Studies on Free Radical Modified Human DNA by Abdi, Saba
STUDIES ON FREE RADICAL 
MODIFIED HUMAN DNA 
ABSTRACT 
THESIS SUBMITTED FOR THE DEGREE OF 
Bottor of $I)tIo!B!op]^p 
IN 
BIOCHEMISTRY 
BY 
SABA ABDI 
DEPARTMENT OF BIOCHEMISTRY 
FACULTY OF MEDICINE 
JAWAHARLAL NEHRU MEDICAL COLLEGE 
ALIGARH MUSLIM UNIVERSITY 
ALIGARH <iNDIA) 
1998 
STUDIES ON FREE RADICAL 
MODIFIED HUMAN DNA 
ABSTRACT 
THESIS SUBMITTED FOR THE DEGREE OF 
Bottor of ^Ul^aophV 
IN 
BIOCHEMISTRY 
8Y 
SABA ABDI 
DEPARTMENT OF BIOCHEMISTRY 
FACULTY OF MEDICINE 
JAWAHARLAL NEHRU MEDICAL COLLEGE 
ALIGARH MUSLIM UNIVERSITY 
ALIGARH (INDIA) 
199d 
The generation of free radicals in aerobes is ubiquitous and there is 
overwhelming evidence that reactive oxygen species (ROS) can cause 
cellular damage. Among the various oxygen free radicals, hydroxyl radical 
(OH) is notably, most reactive species and induces conformational 
changes in DNA including strand breaks, base modifications, damage to 
tumor supprressor gene and enhanced expression of protooncogenes. The 
accumulation of such lesions in DNA has been suggested to significantly 
contribute to carcinogenesis. The release of ROS modified DNA as a result 
of apoptosis may lead to presentation of unique epitopes that might trigger 
antibody response to DNA as in systemic lupus erythematosus (SLE). SLE 
is a multifactorial, autoimmune disease characterized by the presence of 
autoantibodies against various nuclear components of the cell such as 
DNA, RNP and histones. B-DNA per se is a poor immunogen, whereas, 
DNA modified with ROS or certain chemicals have been found to result 
in the generation of SLE anti-DNA autoantibodies . 
In this study, aqueous solution of purified commercially available 
human placental DNA was exposed to hydroxyl radicals generated by 
ultraviolet (UV) irradiation of hydrogen peroxide. The structural and 
conformational alterations in DNA following exposure to *0H radical were 
studied by UV and CD-spectroscopy, thermal denaturation studies, 
hydroxyapatite column chromatography, sedimentation in alkaline sucrose 
density gradient and nuclease SI sensitivity assay. 
The UV spectra of ROS-human DNA exhibited hypochromicity at 
^ s u g g e s t i n g free radical induced base modification. Circular dischroism 
1 1 
spectral analysis showed 75% decrease in ellipticity of human DNA 
following ROS modification. The thermal denaturation studies indicated 
a netdecreaseof 12.5°C inT value of human DNA after ROS modification. 
in 
These results, indicate reduced base stacking, disruption of hydrogen 
bonding and generation of single strand breaks in ROS-human DNA. 
The decreased affinity of ROS-human DNA towards hydroxyapatite 
column and diffused sedimentation profile when subjected to alkaline 
sucrose density gradient ultracentrifugation, also confirmed helix 
destabilization and generation of single strand breaks in ROS-human DNA. 
The single strand breaks in ROS modified DNA were found to be large 
enough to act as substrates for nuclease SI digestion. Acid hydrolyzed 
ROS-human DNA when analysed through DEAE Sephadex A-25 
chromatography revealed modifications in all the four bases. The 
modification was found to be 55% for guanine, 33.3% for thymine, 30% 
for cytosine and 16% for adenine. 
Unlike native human DNA, ROS-human DNA was found to be highly 
immunogenic, inducing high titre (>1:12800) antibodies in rabbits. Thus, 
it can be inferred that human DNA is transformed into an immunogenic 
state following exposure to ROS. 
The anti-ROS human DNA antibodies, though highly specific for 
the immunogen, mimicked SLE autoantibodies by showing considerable 
cross-reactivity towards native DNA, synthetic polynucleotides as well 
as nuclear proteins. This polyspecific behaviour of induced antibodies 
could be due to some common antigenic determinants on the immunogen 
i l l 
and the cross-reacting antigen. 
The light microscopic study, of renal biopsy of rabbits immunized 
with ROS-human DNA revealed glomerular nephritis like condition while 
the immunofluorescence studies showed typical deposition of immune 
complexes in the kidney glomeruli. The studies further indicate that ROS-
human DNA enforces some SLE like characteristics in the immunized 
rabbits and suggests involvement of ROS-human DNA in production of 
SLE anti-DNA autoantibodies. 
The antigenicity of ROS-human DNA was further investigated by 
characterizing SLE autoantibodies for their binding towards native and 
ROS-human DNA. comparative binding of SLE sera to calf thymus and 
human placental DNA suggests SLE autoantibodies to be more specific 
for the latter. Thus, for further investigations human DNA was used in 
order to optimize binding conditions. Both competition ELISA and gel 
retardation assay revealed greater specificity of circulating SLE 
autoantibodies towards ROS-human DNA. 
Similarly sera of various cancer patients were screened for presence 
of circulating antibodies against native and ROS-human DNA. For this 
study, sera of various patients with cancer of either larynx, breast, oral 
cavity, lung, liver, gastrointestinal tract, cervix, penis, bladder, bone or 
Non-Hodgkin's lymphoma showed a higher binding to ROS-human DNA 
as tested by direct binding ELISA. The binding specificity of antibodies 
in these sera to native and ROS-human DNA was assessed by competitive 
binding assay. 
I V 
The higher binding to ROS-human DNA exhibited by more that 80% 
of serum samples collected from patients with malignancies of respiratory 
system suggests the involvement of ROS modified DNA in development 
of these malignancies. Five, out of six patients suffering from breast cancer 
showed higher reactivity towards ROS-human DNA towards its native 
analog. In case of hepatocellular cancer, four out of five serum samples 
tested showed greater recognition of ROS-human whereas for cancer of 
gastrointestinal tract all the three serum samples tested showed greater 
binding to ROS-human DNA. 
Similar results were also obtained for cancer of prostate, cervix, 
bladder, bone and Non-Hodgkin's lymphoma. These results suggest role 
of ROS-human DNA in production of autoantibodies in cancer patients. 
A preliminary study, done on a group of cancer patients undergoing 
radiotherapy revealed decrease in level and specificity of antibodies 
recognizing both native and ROS-human DNA following radiotherapy. 
The role of ROS in development of cancer was further supported 
by detection of oxidative lesions in DNA isolated from lymphocytes of 
various cancer patients, using anti-ROS-human DNA-IgG as probe. DNA 
from patients with breast cancer recognized anti-ROS-human DNA-IgG, 
appreciably and inhibited its activity in the range of 42% to 60%. A 
maximum of 57% inhibition was observed in case of DNA from cancer of 
head and neck DNA isolated from lung cancer patients exhibited 32.5% 
inhibition whereas DNA from patient with gall bladder and cervix cancer 
showed maximum inhibition of 58% and 76% respectively. 
From this study, it can be concluded that exposure of human DNA 
to reactive oxygen species renders it immunogenic. The antibodies induced 
against ROS-human DNA though, highly specific for the immunogen 
showed some degree of cross-reactivity and hence resembled binding 
characteristics of SLE anti-DNA autoantibodies. These results indicate 
possible role of ROS modified DNA in induction of anti-DNA response 
in SLE. Higher recognition of ROS-human DNA by antibodies in sera of 
patients with cancer and/or SLE suggests ROS induced oxidative DNA 
damage in the patients. Further the anti-ROS-human DNA-IgG raised in 
experimental animal was also able to detect oxidative lesions in DNA of 
cancer patients. 
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The generation of free radicals in aerobes is ubiquitous and there is 
overwhelming evidence that reactive oxygen species (ROS) can cause 
cellular damage. Among the various oxygen free radicals, hydroxyl radical 
(OH) is notably, most reactive species and induces conformational 
changes in DNA including strand breaks, base modifications, damage to 
tumor suppressor gene and enhanced expression of protooncogenes. The 
accumulation of such lesions in DNA has been suggested to significantly 
contribute to carcinogenesis. The release of ROS modified DNA as a result 
of apoptosis may lead to presentation of unique epitopes that might trigger 
antibody response to DNA as in systemic lupus erythematosus (SLE). SLE 
is a multifactorial, autoimmune disease characterized by the presence of 
autoantibodies against various nuclear components of the cell such as 
DNA, RNP and histones. B-DNA per se is a poor immunogen, whereas, 
DNA modified with ROS or certain chemicals have been found to result 
in the generation of SLE anti-DNA autoantibodies . 
In this study, aqueous solution of purified commercially available 
human placental DNA was exposed to hydroxyl radicals generated by 
ultraviolet (UV) irradiation of hydrogen peroxide. The structural and 
conformational alterations in DNA following exposure to 'OH radical were 
studied by UV and CD-spectroscopy, thermal denaturation studies, 
hydroxyapatite column chromatography, sedimentation in alkaline sucrose 
density gradient and nuclease SI sensitivity assay. 
The UV spectra of ROS-human DNA exhibited hypochromicity at 
>t^ ^^  suggesting free radical induced base modification. Circular dischroism 
1 1 
spectral analysis showed 75% decrease in ellipticity of human DNA 
following ROS modification. The thermal denaturation studies indicated 
a netdecrease of n.S^C in T value of human DNA after ROS modification. 
m 
These results, indicate reduced base stacking, disruption of hydrogen 
bonding and generation of single strand breaks in ROS-human DNA. 
The decreased affinity of ROS-human DNA towards hydroxyapatite 
column and diffused sedimentation profile when subjected to alkaline 
sucrose density gradient ultracentrifugation, also confirmed helix 
destabilization and generation of single strand breaks in ROS-human DNA. 
The single strand breaks in ROS modified DNA were found to be large 
enough to act as substrates for nuclease SI digestion. Acid hydrolyzed 
ROS-human DNA when analysed through DEAE Sephadex A-25 
chromatography revealed modifications in all the four bases. The 
modification was found to be 55% for guanine, 33.3% for thymine, 30% 
for cytosine and 16% for adenine. 
Unlike native human DNA, ROS-human DNA was found to be highly 
immunogenic, inducing high titre (>1:12800) antibodies in rabbits. Thus, 
it can be inferred that human DNA is transformed into an immunogenic 
state following exposure to ROS. 
The anti-ROS human DNA antibodies, though highly specific for 
the immunogen, mimicked SLE autoantibodies by showing considerable 
cross-reactivity towards native DNA, synthetic polynucleotides as well 
as nuclear proteins. This polyspecific behaviour of induced antibodies 
could be due to some common antigenic determinants on the immunogen 
I l l 
and the cross-reacting antigen. 
The light microscopic study, of renal biopsy of rabbits immunized 
with ROS-human DNA revealed glomerular nephritis like condition while 
the immunofluorescence studies showed typical deposition of immune 
complexes in the kidney glomeruli. The studies further indicate that ROS-
human DNA enforces some SLE like characteristics in the immunized 
rabbits and suggests involvement of ROS-human DNA in production of 
SLE anti-DNA autoantibodies. 
The antigenicity of ROS-human DNA was further investigated by 
characterizing SLE autoantibodies for their binding towards native and 
ROS-human DNA. comparative binding of SLE sera to calf thymus and 
human placental DNA suggests SLE autoantibodies to be more specific 
for the latter. Thus, for further investigations human DNA was used in 
order to optimize binding conditions. Both competition ELISA and gel 
retardation assay revealed greater specificity of circulating SLE 
autoantibodies towards ROS-human DNA. 
Similarly sera of various cancer patients were screened for presence 
of circulating antibodies against native and ROS-human DNA. For this 
study, sera of various patients with cancer of either larynx, breast, oral 
cavity, lung, liver, gastrointestinal tract, cervix, penis, bladder, bone or 
Non-Hodgkin's lymphoma showed a higher binding to ROS-human DNA 
as tested by direct binding ELISA. The binding specificity of antibodies 
in these sera to native and ROS-human DNA was assessed by competitive 
binding assay. 
I V 
The higher binding to ROS-human DNA exhibited by more that 80% 
of serum samples collected from patients with malignancies of respiratory 
system suggests the involvement of ROS modified DNA in development 
of these malignancies. Five, out of six patients suffering from breast cancer 
showed higher reactivity towards ROS-human DNA towards its native 
analog. In case of hepatocellular cancer, four out of five serum samples 
tested showed greater recognition of ROS-human whereas for cancer of 
gastrointestinal tract all the three serum samples tested showed greater 
binding to ROS-human DNA. 
Similar results were also obtained for cancer of prostate, cervix, 
bladder, bone and Non-Hodgkin's lymphoma. These results suggest role 
of ROS-human DNA in production of autoantibodies in cancer patients. 
A preliminary study, done on a group of cancer patients undergoing 
radiotherapy revealed decrease in level and specificity of antibodies 
recognizing both native and ROS-human DNA following radiotherapy. 
The role of ROS in development of cancer was further supported 
by detection of oxidative lesions in DNA isolated from lymphocytes of 
various cancer patients, using anti-ROS-human DNA-IgG as probe. DNA 
from patients with breast cancer recognized anti-ROS-human DNA-IgG, 
appreciably and inhibited its activity in the range of 42% to 60%. A 
maximum of 57% inhibition was observed in case of DNA from cancer of 
head and neck. DNA isolated from lung cancer patients exhibited 32.5% 
inhibition whereas DNA from patient with gall bladder and cervix cancer 
showed maximum inhibition of 58% and 76% respectively. 
From this study, it can be concluded that exposure of human DNA 
to reactive oxygen species renders it immunogenic. The antibodies induced 
against ROS-human DNA though, highly specific for the immunogen 
showed some degree of cross-reactivity and hence resembled binding 
characteristics of SLE anti-DNA autoantibodies. These results indicate 
possible role of ROS modified DNA in induction of anti-DNA response 
in SLE. Higher recognition of ROS-human DNA by antibodies in sera of 
patients with cancer and/or SLE suggests ROS induced oxidative DNA 
damage in the patients. Furdier the anti-ROS-human DNA-IgG raised in 
experimental animal was also able to detect oxidative lesions in DNA of 
cancer patients. 
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The structure of DNA was elucidated by Watson and Crick in 1953 
and it was generally assumed that genomic DNA, in view of its vital role 
in transferring hereditary information from generation to generation, is a 
stable molecule unaltered in its structure by the surrounding events. This 
concept about DNA stability turned out to be a myth when a number of 
variations in conformation of its basic structure were described (Adams et 
al., 1981; Richer a/., 1984; Pechenaya, 1993). DNA double helix can adopt 
multiple conformations such as A, B and Z, each family having its own 
intrinsic restrictions on chain folding and structure (Watson and Crick, 
1953; Arnott, 1976; Drew and Dickerson, 1981). In hydrated medium DNA 
is found in right handed B-form which is the most accepted structure of 
DNA molecule. A-DNA is formed under conditions of low water content 
and is usually not associated with living system (Saenger, 1984; Setlow, 
1992). It is characterized by more base pairs per turn of the helix and a 
wider minor groove than B-DNA, unlike A and B-forms, Z-DNA has a right 
handed helix and phosphate groups in its back bone are zigzagged (Rich et 
al., 1984; Pietrasanta el al, 1994). 
DNA is made up of rather ordinary molecules that are not endowed 
with any peculiar kind of quantum mechanical stability thus, it can undergo 
all kinds of structural and chemical modification when exposed to internal 
(spontaneous) or external (environmental) damaging factors. (Rao, 1993; 
Wiseman and Halliwell, 1996; Henle and Linn, 1997). Various causative 
agents, that induce damage to DNA in living organisms, have been 
summarized in Table-1. 
TABLE - 1 
Various Endogenous and Exogenous Factors/Sources 
of DNA Damage* 
Endogenous (spontaneous) sources 
Normal body temperature (37°C) 
Normal cellular metabolism 
Free radicals produced during metabolism 
Errors in DNA replication and repair 
High levels of reducing sugars 
Methylating compounds like S-adenosyl methionine 
Exogenous (environmental) sources 
Dietary mutagenic compounds 
UV and ionizing radiations like X-rays, y-rays. 
Free radicals (produced because of a variety of factors including 
ionizing radiations) 
Heavy metals 
Ultrasound 
* From; Rao. K.S. (1993) Genomic Damage and its Repair in Young and Aging Brain. 
Molecular Neurobiology 7, 23-48. 
Free Radicals 
A free radical may be defined as any chemical species that contain 
one or more unpaired electrons (Halliwell and Gutteridge, 1989). They 
are extremely reactive, hence their half lives are very short and steady 
state concentrations are quite low (Freeman 1984; Halliwell and Gutteridge, 
1984; Cadenas, 1989). This broad definition of free radical includes the 
hydrogen atom (one unpaired electron), most transition metals and the 
oxygen molecule itself (Halliwell and Gutteridge, 1984). Although oxygen 
is a powerful oxidant, the triple ground state of dioxygen constitutes a 
kinetic barrier for oxidation of biological molecules, which are mostly in 
singlet state (Henle and Linn, 1997). Therefore in most oxidation reactions, 
oxygen has to be "activated" to take part in the reaction (Hayaishi, 1974; 
Foote, 1976). The term "activated oxygen" may be applied to many oxygen 
free radicals such as singlet oxygen ('O2), superoxide radicals (O2 ), 
hydrogen peroxide (H2O2), hydroxyl radicals (*0H), peroxy radicals (RO'^) 
and hydroperoxides (ROOH) (Singh, 1982). 
Superoxide anion (O2" ) is formed by single electron transfer to 
ground state dioxygen. During mitochondrial respiration 1-5% of oxygen 
is converted to 02" (Freeman and Crapo, 1982; Cross et al., 1987). 
Superoxide radical shows limited reactivity, but in aqueous solution it 
reacts with itself producing hydrogen peroxide and molecular oxygen in 
presence of enzymes superoxide dismutase (Halliwell, 1994). The 
protonated form of O2"', called perhydroxyl radical (HOj ) is more reactive 
than O2"* itself (Halliwell and Gutteridge, 1989). 
Hydrogen peroxide though not a free radical, is harmful to the cell 
because of its ability to cross biological membranes and produce highly 
reactive hydroxyl radical ('OH) (Ward et al., 1987; Pryor and Church, 1991) 
which is the tri-electron reduction product of molecular oxygen (Halliwell, 
1992; Luft, 1994). It is extremely reactive with very short half life (fraction 
of a microsecond) as a result its radius of action is limited to just 30° A. 
Superoxide and H^O^ though less reactive than 'OH, have a longer half life 
and react with molecules far away from their site of production (Halliwell 
and Gutteridge, 1984; Pryor, 1986). 
Fenton (1894) first reported that H2O2 acts as a much stronger oxidant 
when decomposed by the ferrous ions 
H2O2+ Fe2"-^Fe^"+ OH + OH" 
Later Haber and Weiss (1934) postulated that O^' interacts with H^O^to 
form hydroxyl radical. 
H^O^+O^"- ^ 0 ^ + OH" + -OH 
The above mentioned reaction is known as Haber-Weiss reaction. 
In living cells reactive oxygen species (ROS) are produced 
continuously during normal aerobic metabolism (Halliwell and Aruoma, 
1991) as well as in many pathologic conditions such as tissue ischemia, 
cancer, inflammation and degenerative diseases (Halliwell and Gutteridge, 
1984; Vuilaume, 1987). 
The autooxidation of certain small cytoplasmic molecules such as 
catecholamine, flavins and the activity of some enzymes (xanthine oxidase 
and aldehyde dehydrogenase) have been known to produce ROS, in vivo 
(Fridovich, 1983). Besides these, the metabolism of arachidonic acid and 
respiratory burst from phagocytes also give rise to ROS (Halliwell and 
Gutteridge, 1989). 
A recent study, reveals that iron has the ability to substitute for zinc 
in the DNA-binding domain (zinc finger) of the estrogen receptor. It has 
been demonstrated that iron fingers in presence of H^O^ and ascorbate 
generates 'OH which cause cleavage of proximate DNA (Conte et al., 1996). 
Beside these exogenous sources, ROS are also generated by a number of 
endogenous sources such as inhaled smoke, polluted air, certain ingested 
food and a variety of carcinogens (benzene, aflatoxin, benzo(a)pyrene (Frie 
et al., 1991; Kolachana et al., 1993; Mauthe et al, 1995; Nagashima et 
al., 1995; Shen et al., 1995). 
The low wavelength ionizing radiations (eg. y and X-ray) and 
ultraviolet (UV) light are also important exogenous sources of ROS (Davies, 
1987; Epe, 1991). Hydroxyl radical is also known to be generated by UV 
(254 nm) irradiation of H202(Ara and AH, 1992 & 1993). Various sources 
of pathogenic ROS have been summarized in Table-2. 
Oxidative DNA Damage 
Oxidative stress results either due to over production of ROS or 
inadequate antioxidant defences (Sies, 1991). Subjecting cells to oxidative 
stress leads to severe metabolic dysfunctions including lipid peroxidation 
depletion of nicotinamide nucleotides, rise in intracellular free Ca^" ions, 
cytoskeleton disruption and DNA damage (Halliwell and Aruoma, 1991; 
Wiseman and Halliwell, 1996). 
TABLE - 2 
Sources of Pathogenic Reactive Oxygen Species* 
Endogenous 
1. Phagocytic cells stimulated by tumor promoters through: 
Protein kinase C activation (TPA, mezerein, RPA, teleocidin, 
thapsigargin) 
Phosphatase inhibition (okadaic acid, palytoxin) 
Unknown mechanism (NijS^, NiS^, NiS, CdS, CaCrO^) 
2. Non-phagocytic cells (epidermal keratinocytes, HeLa, MRCS, lOTl/2 and 
others) 
Treated with tumour promoters 
Metabolizing complete carcinogens (PAHs, nitro- and amino-
polyaromatics, diethylstilbestrol (DES), metals (Cr, Ni, Hg, Cu) 
3. Quinone - semiquinone redox cycling 
4. Induction of pro-oxidant enzymes 
Xanthine oxidase 
5. Inhibition of antioxidant enzymes 
6. Induction of fatty acid and CoA oxidases by peroxisome proliferaters 
7. Ischemia / reperfusion 
Exogenous 
1. Ionizing radiations (y, X-ray,^H,U.V.) 
2. Cigarette smoke 
3. Chewing betel nuts 
4. Ozone 
5. Quinone antibiotics, chemotherapeutic agents, pesticides. 
* From : Frenkel, K (1992) Carcinogen - Mediated Oxidant Formation and Oxidative DNA Damage. 
Pharmac. Ther. 53. 127-166. 
Since the cell is particularly sensitive to DNA damage, genetic and 
physical effects of oxidative stress upon cellular DNA are well documented 
(Imlay and Linn, 1988; Halliwell and Aruoma, 1991; Breen and Murphy, 
1995; Wiseman and Halliwell, 1996; Henle and Linn, 1997). The oxidative 
damage to DNA can be explained by two mechanisms. First possibility is, 
OH mediated DNA damage (Halliwell and Gutteridge, 1989). A second 
explanation is that oxidative stress triggers off a series of metabolic events 
within the cell, that lead to activation of nuclease enzymes which cleave 
the backbone (Birnboin, 1988). These mechanisms of oxidative stress are 
not mutually exclusive i.e.they can both take place in vivo (Imlay and Linn, 
1988; Dypbukt et al., 1990). 
The attack by ROS upon DNA produces a multiplicity of different 
products, such as a range of specifically oxidized purines, pyrimidines, 
abasic sites, alkali labile sites, chain breaks and DNA-protein cross-links 
(Breen and Murphy, 1995; Cadet et al., 1997). In conditions involving high 
levels of ROS, single strand breaks in close proximity may also result in 
the formation of double strand breaks (Vamvakas et al., 1997). 
The components of DNA most susceptible to the radical action are 
the thymine and cytosine bases, followed by adenine, guanine and finally 
the deoxyribose sugar (Demple and Linn, 1982; Hutchinson, 1985; 
Yamamoto and Kawanishi, 1989; Rosen et al., 1996). However, for double-
stranded DNA, the deoxyribose moiety is modified more frequently than 
the bases, due to its exterior location in the helix (Imlay and Linn, 1988; 
Demple, 1990). Damage to sugar moiety of DNA includes abstraction of 
hydrogen from one of the deoxyribose carbons and the predominant 
consequence is strand breakage and base release (Henle et al., 1995). 
Another alternation at the sugar moiety is p to oc inversion at the 1' carbon, 
resulting in disruption of B-DNA structure (Ide et al., 1994). 
Free radical attack on DNA bases results primarily in addition of OH 
group to the electron rich double bonds, particularly the purines N(7)-N 
(8) bond and the pyrimidine 5,6-bond (Henle et al., 1996; Luo et al., 1996). 
Hydrogen abstraction from thymine-methyl groups also occurs (von 
Sonntag, 1987b). Among the oxidized purines, formamidopyrimidines 
(FAPy) and 7,8-dihydro-8-oxoguanine (8-oxo-G), have received widespread 
study, whereas among the pyrimidines, thymine glycol and its hydrolysis 
products have been actively studied, most likely because of the ubiquitous 
presence of enzymes for the excision of all the products (Henle and Linn, 
1997). 8-oxo-G is one of tke most abundant base lesions formed by 
ultraviolet (Floyd et al., 1988) and ionizing radiations (Kasai et ah, 1986). 
It is highly mutagenic (Moriya, 1993) and is used as a specific marker of 
oxidative damage to DNA and allows for the study into possible DNA 
reactions in vivo (Kasai et al., 1986). Oxidatively damaged DNA was found 
to contain 8 to 83, 8-oxo-G residues/ lO^deoxyguanosine. Quantitation of 
8-oxo-G can be done with high sensitivity by high performance liquid 
chromatography coupled with electrochemical detection (HPLC-ECD) 
(Floyd et al., 1986). 
Other oxidative modifications of purines and pyrimidines include.S 
-oxoadenine, 2-hydroxyadenine, FAPy-adenine, 5-hydroxymethyl uracil, 5-
hydroxycytosine, cytosine glycol and thymine glycol. The yield of the 
individual DNA modification is highly dependent on which reactive oxygen 
species are involved. Thus, where as singlet oxygen induces preferentially 
8-oxo-dG (Epe, 1991), superoxide has too lowreactivity to induce this 
modification at all (Fischer-Nielsen et al., 1994) and hydroxyl radicals 
can cause almost all modifications (Dizdaroglu, 1991). In addition, the 
target molecule conditions such as oxygen tension, chelation of the 
transition metal ions and the presence of reductants may influence the 
yield and pattern of oxidative DNA modifications (Dizdaroglu, 1991 & 
1994). 
Systemic Lupus Erythematosus 
The immune system is designed to defend an individual from a variety 
of foreign insults, while not responding to one's own self antigens (Tsao 
and Hahn, 1994). A complicated mechanism called self tolerance avoids 
autoreactivity, however, breakdown of this self-nonself discrimination 
mechanism leads to copious production of autoantibodies and autoreactive 
T cells, responsible for autoimmune diseases (Deodhar, 1992). 
Systemic lupus erythematosus (SLE) is one such non-organ specific 
autoimmune disease, characterized by a plethora of abnormal immune 
phenomenon including prolific autoantibody production, circulating 
immune complexes, complement activation and immune-complex mediated 
target organ damages (Pisetsky, 1996; Klippel, 1997). 
The annual incidence of SLE is 50 to 70 per million and prevalence 
is 500 per million population. The highest incidence of this disease is 
observed among women aged 20 to 70 years (Klippel, 1997). The criteria 
defining SLE have been listed in Table-3. 
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TABLE - 3 
The Revised 1982 Criteria for Classification of Systemic Lupus 
Erythematosus* 
Criterion Definition 
Macular rash 
Disord rash 
Photosensitivity 
Oral ulcers 
Arthritis 
Serositis 
Renal disorder 
Neurologic disorder 
Hematologic disorder 
Immunologic disorder 
ANA 
Flat or raised 
Erythematous raised patches with 
kertatotic scaling 
Skin rash due to exposure to 
sunlight 
Usually painless 
Nonerosive, usually non-sysmmetrical, 
characterized by tenderness, 
swelling, or effusion 
Pleuritis or pericarditis 
Proteinuria greater than 0.5g/day, or 
cellular casts 
Seizures or psychosis 
Hemolytic anemia, leukopenia, 
thrombocytopenia 
Positive LE cells, anit-DNA antibody 
to native DNA, anti-Sm 
false-positive test for syphilis by 
cardiolipin test 
In the absence of drug-induced 
lupus 
*From: Levincon, S.S. (1994) Humoral Mechanisms in Autoimmune Disease. Journal of Clinical 
Immunoassay, 17, 72-84. 
+Four of these criteria are required for the diagnosis of SLE. 
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The clinical manifestations of SLE are remarkably heterogenous 
commonly including arthritis, vasculitis and glomerulonephritis (Klippel, 
1997). Hallmark of SLE are the autoantibodies directed towards a variety 
of intracellular antigens including nucleic acids, proteins andnucleoproteins 
(Table-4). More than any other autoantibody in SLE, anti-DNA autoantibody 
has emerged as a valuable marker for diagnosis and prognosis (Kanda et 
al., 1997; Neparstek and Madaio, 1997). Thus, most clinical assays of SLE 
patients are designed to detect anti-dsDNA antibodies because of their 
increased specificity for diagnosis (Takeuchi et al., 1997). 
The anti-DNA autoantibodies are found to be most uniquely 
correlated with SLE and its period of clinical activity especially with its 
renal manifestations (Stollar, 1981; Kitani et al., 1992; Vlahakos et al., 
1992; Hahn et al., 1993). It is generally appreciated that anti-DNA 
antibodies are important contributors to glomerular immune deposit 
formation in individuals with systemic lupus erythematosus (Koffler et al., 
1967; Hahn, 1980; Wilson, 1991). Although, majority of anti-DNA 
antibodies do not have proven pathogenic role in SLE, however some of 
them may at least in part be responsible for the lesions in SLE, in 
conjucture with other still unknown factors (Sany, 1990). Recent perfusion 
experiments in vitro and in vivo with anti-dsDNA antibodies and the 
presence of such antibodies in diseased kidneys of both human and mouse 
with SLE, have convinced most investigators that these antibodies 
contribute to kidney damage (Raz et al., 1989; Tsao et al., 1990). 
Serological findings too suggest that lupus nephritis results from the 
deposition of DNA-anti-DNA complexes and subsequent complement 
mediated tissue damage (Emlen et al., 1986). 
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TABLE - 4 
Cellular Antigens Reactive with SLE Sera* 
Nucleic acids 
Native DNA 
Denatured DNA 
Double-stranded RNA 
tRNA, ribosomal RNA, viral RNA 
Poly (ADP-ribose) 
Nucleoproteins 
DNA-histone 
Nuclear ribonucleoproteins (Sm, Mo) 
Cytoplasmic ribonucleoprotein (Ro=SSA, La=SSB) 
Ribosomes 
Proteins 
Histones 
* From; Stollar, B.D. (1981) Anti-DNA Antibodies. Clinics in Immunolog) and Allergy 1. 243-260 
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Hydridoma technology and antibody sequencing have facilitated 
enormously the dissection of anti-DNA antibodies into features which may 
impart pathogenicity and/or allow DNA recognition. Typically, the high 
affinity anti-dsDNA IgG which is cationic, produces tissue damage 
(Sagawa, 1992; Suzuki et al., 1993). 
The anti-DNA antibodies found in SLE sera are known to be 
polyspecific and have been shown to recognize epitopes that occur not 
only on differing nucleic acids (Andrezewski et al., 1980; Swanson et al., 
1996) but also on phospholipids (Tiikainem et al., 1991) proteins (Pisetsky 
et al., 1985; Tsuzaka et al., 1996), polysaccharides (Kashihara et al., 
1985) and cell membrane structures (Jacobe/ al., 1986). This polyspecificity 
of anti-DNA autoantibodies could be due to variable binding sites in 
individual immunoglobulin or to recurrent epitopes in different antigens. 
The polyreactivity of anti-DNA autoantibodies suggest that DNA itself 
may not be the immunogen responsible for what are known as anti-DNA 
antibodies. Thus, the exact antigen responsbile for anti-DNA autoantibody 
production remains an enigma. 
It may be possible that there is fundamental breakdown of immune 
regulatory networks so that some normally suppressed B cells are released 
to produce their product, anti-DNA antibody, in absence of specific 
immunizing stimulus (StoUar, 1981). 
Recently studies have suggested that altered apoptosis, occuring in 
SLE patients (Emlen et al, 1994) might provide a source of extracellular 
nuclear antigen to drive the immune response (Casciola-Rosen and Rosen, 
1997).This suggestion can be further emphasised upon by studies which 
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demonstrate that clearance of apoptic cell material by phagocytosis is 
described in SLE patients, leading to accumulation and presentation of 
autoantigens and thus possibly triggering an autoantibody response 
(Herrmann era/., 1996). 
Antigenicity of DNA 
The association of anti-DNA autoantibody with SLE was enforced 
by efforts to replicate SLE by immunization of normal animals with DNA 
(Levine et al., 1960; Holloran and Parker, 1966). However, native dsDNA 
failed to elicit significant antibody production (Madaio et al., 1984). In 
contrast, conformations of DNA other than the native form (B-form) such 
as Z-DNA and certain synthetic nucleic acid polymers like poly(dT), poly 
(dC), poly(dA), poly(dl) and poly(G) can induce antibodies that react 
selectively with the immunogen (Stollar, 1986; Braun and Lee, 1988, Garg 
and AH, 1998). Besides these, DNA modified with hormones, drugs and 
ROS have also been reported to induce antibodies. (Moinuddin and Ali, 
1994; Arjumand et al., 1995; Ashok and Ali, 1998). 
Thus, chemically or physically modified DNA or helical structures 
that differ significantly from B-form are stronger immunologic stimuli than 
native DNA. However, most of the antibodies induced by modified DNA 
do not react with its unmodified form (Anderson et al., 1988). 
As shown by recent research, the immunological properties of DNA 
vary strikingly with sequence microheterogenity. As a result bacterial DNA, 
in contrast to mammalian DNA, has a powerful immunostimulatory activity 
(Pisetsky, 1996). 
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Antibodies reactive to bacterial DNA have been found to be present 
both in SLE and normal human sera (NHS) (Karounos et al., 1988, Wu et 
al., 1997) however, antibodies from the two sources show major differences 
in immunochemical properties. These differences include specificity for 
conserved versus non-conserved sites on DNA, role of ionic interactions 
in DNA binding, avidity, light chain restriction and isotype profile. Thus, 
NHS anti-DNA are predominantly lgG2 where as SLE anti-DNA is 
predominantly IgGl and IgG3 type . The difference in isotype profile points 
to differences in inducing mechanisms. Thus, while SLE anti-DNA appears 
T-dependent, normal human serum anti-DNA resemble responses to 
bacterial carbohydrate antigens and display features of T-independence 
(Robertson et al., 1992; Wu et al., 1997). 
Studies carried out to investigate the immune response to bacterial 
DNA in SLE indicate that SLE patients have a marked deficiency in the 
production of antibodies specific for bacterial DNA antigen. This 
deficiency could predispose to autoimmunity by failing to eliminate from 
the host a potent stimulus for non-specific immune activation as well as 
DNA antigen drive (Pisetsky and Drayton, 1997). 
Role of ROS in SLE 
There is increasing evidence implicating with the involvement of free 
radicals, particularly those derived from molecular oxygen in various 
diseases involving inflammation (Blake et al., 1987; Halliwell and Aruoma, 
1991; Kunz et al., 1991). This process, which is a response of host organism 
to injury, involves enhanced vascular permeability with edema formation 
and leukocyte infiltration into the damaged area (Lunec et al., 1994). 
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Perpetual stimulation of phagocytic cells by foreign substances such 
as bacterial and other immunological stimuli activates the membrane bound 
NADPH oxidase to cause respiratory burst (Lunec et al., 1987). Reactive 
oxygen species produced during respiratory burst of phagocytic cells, plays 
an essential role in bacterial killing and in regulating the process of acute 
inflammation (Babior, 1978; Halliwell, 1982). As can be seen, inflammatory 
response is advantageous for organisms. However, abnormal overactivation 
of phagocytes with consequent exacerbation of reactive oxygen metabolites 
production may damage surrounding tissues and lead to diseases such as 
SLE (Proctor and Reynolds, 1984; Southorn and Powis, 1988; Halliwell 
and Gutteridge, 1989). 
Oxygen derived free radicals are known to be involved in the 
pathobiology of SLE, particularly in respect of processes leading to the 
formation of pathological anti-DNA antibodies. It has been suggested that 
activated phagocytic cells release ROS (Allan et al., 1988) which penetrate 
cellular membrane, interact with nuclear DNA and lead to its modification 
(Bashir et al., 1993). Such modification of DNA increases its 
immunogenicity, thus trigerring production of anti-DNA autoantibodies 
(Blount et al., 1992). 
The extent of genomic DNA damage by ROS in SLE can be estimated 
by measuring the content of 8-oxo-7-hydrodeoxyguanosine (8-oxo-dG), a 
promutagenic DNA lesion induced by ROS (Bashir et al., 1993). The 
lymphocytes isolated from patients suffering from SLE contain increased 
levels of 8-oxo-dG in DNA (Bashir et al., 1993). A study of cultured blood 
monocytes isolated from SLE patients showed reduced capacity for repair 
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of 8-oxo-dG induced by incubation with hydrogen peroxide (Lunec et al., 
1994). In DNA isolated from immune complexes precipitated from plasma 
of SLE patients 8-oxo-dG was found to be 100-fold more abundant than the 
usual values in nuclear DNA (Lunec et al., 1994). This oxidatively modified 
DNA may be a source of the anti-DNA autoantibodies characteristic for 
SLE. 
The SLE patients may suffer from an increased rate of oxidative DNA 
damage and a deficient repair systems. This may contribute to the 
pathogenesis and even to the increased risk of malignant diseases in SLE 
patients (Bashir et al., 1993; Lunec et al., 1994). There is increasing 
evidence to suggest a link between SLE and cancer. The expected standard 
incidence ratio for cancer in the lupus patients is 1.36 (Janosky et al., 
1995). Expression of certain proto-oncogenes has also been found to 
increase in lymphocytes of lupus patients (Boumpas et al., 1986). 
Cancer 
Carcinogenesis is the malignant transformation of a cell or group of 
cells (Farber and Cameron, 1980; Potter, 1983; Farber, 1984). This 
multistep process can be divided into two main stages, initiation and 
promotion (Boutwell et al., 1982; Perera, 1991). The initiation phase is 
caused by single exposure to a carcinogenic agent and involves an 
irreversible modification of the genetic material of the cells. On the other 
hand, promotion requires multiple exposure to the promoters to alter gene 
expression and produce a tumour. In contrast to initiation, the promotion 
stage is reversible (Cerutti, 1985; Demple, 1990; Martinez-Cayuela, 1995). 
As with other chronic diseases, cancer too has a multif 
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aetiology which includes both genetic and environmental factors (Gourley 
et al., 1992). The environmental factors are responsible for 80% to 90%, 
of all human cancers. Genetic influence, though long been suspected in 
incidence of cancer, is less conspicuous and more difficult to identify 
(Clemens, 1991). There is probably a complex inter-relationship betw^een 
hereditary susceptibility and environmental carcinogenic stimuli in the 
causation of a number of cancers. 
Among the environmental factors, consumption of tobacco in various 
forms (eg. smoking, chewing) is the major cause of cancer of lung, larynx, 
mouth, pharynx, bladder, pancreas and probably kidney (WHO, 1983). 
Alcohol consumption is associated with cancer of oesophagus, liver and 
rectum (Kabat et al., 1986;Eskelson et al., 1993). Dietary factors such as 
high fat diet, beef consumption, food additives and contaminants have been 
related to cancer (Ames, 1983). 
Occupational exposures to benzene, arsenic, cadmium, chromium etc. 
have also been known to cause cancer (Kasai and Nishimura, 1984; Frenkel, 
1992; Kolachana et al., 1993; Lagorio et al., 1994). Viruses such as 
Hepatitis B and C virus are causally related to hepatocellular carcinoma 
(Blumberg et al., 1975). Recently, bacterial infections have also been linked 
to cancer (Parsonnet, 1995).A number of other environmental factors such 
as sunlight, radiations, pesticides and medications (eg. estrogen) too are 
known to be related to cancer (Anathaswamy and Pierceall, 1990; Liehr, 
1997). 
Studies indicate that most of these exogenous carcinogens act via 
production of reactive oxygen species (Frenkel, 1992; Leanderson, 1993; 
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Feig et al., 1994, Erhardt et al., 1997). Thus reactive oxygen species 
produced exogenously as well as endogenously are known to play an 
important role in the initiation and promotion of multistage carcinogenesis 
(Totter, 1980; Ames, 1989; Toyokuni et al., 1994; Sadani and Nadkarni, 
1996; Pryor, 1997). 
Role of ROS in Cancer 
The complex series of cellular and molecular changes that occur 
through the development of cancer can be mediated by a diversity of 
endogenous and exogenous stimuli (Frenkel, 1992). DNA appears most 
important in tumor biology since it is firmly established that cancer is a 
genetic disease (Cotran et al., 1989) and DNA damage is thought to be 
involved in all stages of carcinogenesis (Halliwell and Gutteridge, 1989; 
Vile and Morris, 1992; Olinski, 1993). 
Any agent capable of chemically modifying DNA in cell could be 
carcinogenic. Thus, reactive oxygen species known to cause oxidative 
damage to DNA, are potent carcinogens (von Sonntag, 1987a; Halliwell and 
Aruoma, 1991; Dizdaroglu, 1992; Cerutti et al, 1994; Loft and Poulsen, 
1996). Although chromatin may offer some protection against oxidative 
damage to DNA (Ljungman and Hanawalt, 1992). The antioxidant defence 
and specific repair process present may prevent or correct oxidative 
mutation however, oxidation from both endogenous and exogenous sources 
can overwhelm these defences and lead to mutagenesis . 
ROS acts at several steps in multistage carcinogenesis (Lunec, 1990; 
Clayson et al., 1994; Ames et al, 1995; Drexer et al., 1996; Pryor, 1997). 
Figure 1, shows a simplified model for role of ROS in multistage 
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Fig.l. Role of ROS in multistage carcinogenesis. 
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carcinogenesis. When the mutations caused by ROS relate to critical genes 
such as oncogenes or tumor suppressor genes, initation and/or progression 
of cancer may result (Loft and Poulsen, 1996) . A common site for point 
mutations in both the p53 and retinoblastoma tumor suppressor gene is GC 
base pair in CpG dinucleotide sequences (Hollstein et al., 1991; Haris and 
Hollstein, 1993). Similarly, cellular genes can be converted to oncogenes 
through a single base pair change for example, the most frequent site of 
mutation in the ras family of oncogenes are GC base pairs in codon 12 and 
13 (Bos et al., 1988; Du et al., 1994). GC base pair therefore represent a 
vulnerable target for mutation by oxidative stress. 
Although, ROS damage all four bases in DNA, mutations are usually 
related to modification of GC base pairs (Retel et al., 1993). The most 
abundant of these lesions is 8-oxo-7,8- dihydro-2'- deoxyguanosine (8-oxod 
G) (Halliwell and Aruoma, 1993; Toyokuni et al., 1994). 8-oxo-dG is also 
most mutagenic, resulting in G to T transversions (Kuchino et al., 1987; 
Floyd, 1990; Shibutani et al., 1991). The generation of 8-oxo-dG may 
account for the formation of G^T transversions through mispairing with 
adenine. Besides mispairing, the oxidative products of DNA bases may 
function in mutagenesis through other mechanisms including abnormal 
interactions with the DNA replicative machinery (Feig and Loeb, 1993; 
Weitzman et al., 1994). 
Persistent oxidative stress can also activate transcription factors such 
as NF-xB, through the intracellular signal transduction systems (Schreck 
et al., 1991) and induce expression of protooncogenes such as Q-fos, c-jun 
and c-myc (Crawford et al., 1988; Nose et al., 1991).Oxidative stress has 
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been implicated as an important factor in metastasis, notably because it 
results in a loss of cell adhesion which is the prerequisite for cellular 
detachment and host tissue invasion (Fidler and Nicolson, 1991; Kundu et 
al., 1995). 
Since the cumulative risk of cancer is seen to increase with 
approximately the fourth power of age, thus cancer can be considered as a 
degenerative disease of old age and it is frequently suggested that this too 
is related to the effects of continuous damage, over a life span, by ROS 
(Totter, 1980; Ames, 1989). 
The role of ROS in development of cancer in humans is further 
supported by the presence of oxidative DNA products in cancer tissue. 
The concentration of 8-oxo-dG, expressed as the number of molecules/10^ 
bases, in normal versus cancerous tissue was found to be 7.3 versus 23 in 
lung, 0.94 versus 5.1 in stomach, 3.1 versus 9.2 in ovary and 2.7 versus 
4.4 in colon (Malins and Haimanot, 1991; Olinski et al., 1992; Malins et 
al., 1993). The level of 8-oxo-dG was much higher in invasive ductal 
carcinoma of female breast than in any other type of cancer (Malins and 
Haimanot, 1991; Olinski et al., 1992). Thus, oxidative DNA base damage 
products are generally higher in cancerous tissue. 
Lung cancer is one of the most frequent cancer related cause of death 
in both males and females, and 90% of the cases are due to smoking (Wyder 
and Hoffmann, 1994). A series of events could be involved in the production 
of mutations by component of cigarette smoke, some of which might be 
mediated by DNA damage via oxygen free radicals (Leanderson, 1993). 
Cigarette smoking depletes intracellular antioxidants and increases the 
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number of neutrophils in lung thus increasing the level of oxygen free 
radicals . Tobacco (smoking and smokeless) consumption is also considered 
an important risk factor for oral cancer. Abuse of tobacco generates 
increased production of free r^adicals and elicits immunosuppression 
(Enwonwu and Meeks, 1995). 
Another major cause of cancer mortality in both Africa and Asia is 
the hepatocellular carcinoma. In these countries primary hepatoma is 
associated with either ingestion of aflatoxin (Ross et al., 1992) or with 
chronic infection by hepatitis virus B and C (Blumberg et al., 1975) 
Aflatoxin produces G to T transversion, this transversion can also be 
produced by oxidative damage. Chronic hepatitis is associated with the 
presence of inflammatory cells, presumably generating ROS. The 8-oxo-
dG content in liver with chronic hepatitis has been found to be significantly 
higher than the content in normal liver (Shimoda et al., 1994). Oxygen 
free radicals are also implicated in the mechanisrn of gastric cancer (Salim, 
1992a) and colonic cancer (Salim, 1992b). 
Studies on cancer of breast suggest involvement of oxidative DNA 
damage in the developing stages. Increased steady state levels of DNA 
base damage, with a pattern characteristic of *0H attack, have been reported 
in DNA from invasive ductal carcinoma of breast (Malins and Haimnot, 
1991; Malins et al., 1993). DNA damage by ROS is also implicated in 
inflammatory breast disease (Jaiyesimi et al., 1992) where malignant 
progression can also occur. Evidence has been presented showing that "OH 
modification of DNA is intimately involved in the progression of breast 
tumors to the metastatic state and is likely an important etiologic factor 
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contributing to the high degree of metastatic cell population (Malins et 
al., 1996). 
Prostate cancer is characteristically diagnosed in old age or at autopsy 
and it contributes to the third most frequent cancer related cause of death 
in males in the United States. The paucity of known chemical agents 
associated with prostate cancer and the absence of any apparent 
environmental or occupational risk factors suggests that prostatC/Cancer is 
associated with endogenous cellular processes (Feig et al., 1994). The most 
reasionable canditate for endogenously formed genotoxins that accumulate 
in later life are the reactive oxygen species (Feig et al., 1994). 
The elevated levels of modified bases in cancerous tissues may be 
due in part to the presence of large amounts of leukocytes in human tumors 
(Euler and Alexander, 1987). Activated leukocytes are a source of HjOj, 
which can cross cellular and nuclear membranes and react with nucleus to 
cause site specific DNA damage by producing 'OH in reaction with DNA-
bound metal ions (Halliwell and Gutteridge, 1989; Dizdaroglu et al., 1991). 
Production of large amounts of H202has been found to be characteristic of 
human tumor cells (Szatrowski et al., 1991). 
Cells have evolved an array of antioxidant defences designed to 
severely limit damage caused by free radicals wherever and whenever it 
might occur (Ballmer et al., 1994; Duthie et al., 1996). This situation is 
perhaps the most persuasive argument that exists for the significance of 
free radicals as a threat to viability of cells and organisms. 
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Defence Against Reactive Oxygen Metabolites 
It is established beyond doubt that free radicals in tissues and cells 
can damage DNA, proteins, carbohydrates and lipids (Wiseman and 
Halliwell, 1996). The potentially deleterious reactions of ROS are at least 
partly controled by antioxidants. It is widely believed that a proper balance 
between free radicals and antioxidants is associated for health of an 
organism (Rautalahti and Huttunen, 1994). Defence mechanisms against 
ROS include the following. 
(a) Physical restriction 
Selective compartmentalisation and physical restriction are an 
important feature of defence against deleterious effects of free radical 
reactions. Reactive oxygen metabolite formation is physically restricted 
within the cell so that controlled production and release limits toxicity 
while still allowing the necessary and desirable consequences of single 
electron generation. For example the free radical intermediates produced 
in the electron transport chain are tightly coupled in the membrane bound 
enzymes and carriers, thus protecting membrane polyunsaturated fatty 
acids from lipid peroxidation (Williams, 1985; Lunec and Blake, 1990) 
(b) Control of Superoxide 
The enzyme superoxide dismutase (SOD) catalyses dismutation of 
0 2 " to H^O^. 
o;- + o;- soD> H^O^+^O^ 
The SOD enzymes are a family of metalloproteins. In man one is a 
dimeric copper-zinc based enzyme bound in the cytosol, the other is 
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tetrameric manganese centred form localised to the mitochondrial matrix 
(Singh et al., 1994). Level of SOD in the cell is sensitive to oxygen tension, 
the presence of O2" generating drugs and metal concentrations (Imlay and 
Linn, 1988). 
(c) Control of hydrogen peroxide 
Hydrogen peroxide formed in vivo is reduced either by haemenzyme 
catalase or by the seleno-enzyme, glutathione peroxidase. The latter being 
more effective in removing H^OjCMichiels et al., 1994). 
(i) Catalase 
It functions via a peroxidation reaction 
2H.O.catalse^2H.O + 0^ 
In mammalian cells catalase is largely contained in peroxysomes 
(Amstad et al., 1991) and to lesser extent it is secreted (Sandstrom et al., 
1993). 
(ii) Glutathione peroxidase 
The selenium based enzyme, glutathione peroxidase, will reduce H2O2 
by catalysing its reaction with the reduced form of glutathione (GSH). 
H2O2+ 2GSH glutathiones 2H2O + GSSG 
peroxidase 
Oxidized glutathione (GSSG) is reduced back to GSH by the NADPH 
enzyme glutathione reductase. In eukaryotes, glutathione peroxidases are 
found in the mitochondria, cytoplasm and peroxysomes (Singh et al., 1994). 
The relative levels of SOD, catalase and glutathione peroxidase are 
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important. For instance, an increase in SOD would deplete the cell of 
superoxide but would increase H^Oj production, which might be deleterious 
unless sufficient catalse and / or glutathione peroxidase are available. 
(d) Control of the hydroxyl radical 
Extremely high reactivity of "OH excludes enzymatic control. 
However, its formation can be controlled by compartmentalization of 
transition metals, such as iron and copper which are required for its 
production. Its formation is also influenced by SOD, catalse and glutathione 
peroxidase that limit substrate availability for the Haber-Weiss reaction. 
(i) Iron and Copper compartmentalization 
Iron is compartmentalised in proteins such as ferritin, lactoferrin and 
transferin (Lunec and Blake, 1990). Copper ions are entraped in a protein 
caeruloplasmin (Gutteridge, 1983; Galdston et al., 1984, 1987). 
(ii) Vitamin E and Vitamin C 
Vitamin E (oc-tocopherol) and vitamin C (ascorbic acid) remove free 
radicals by reacting directly with them non-catalytically. (Packer et al., 
1979; Som et al., 1983). 
(e) Control of singlet oxygen 
As yet, an enzymatic apparatus for singlet oxygen removal has not 
been detected, rather the cell appears to employ scavengers such as 
carotenoids (Sies et al., 1995). 
Repair of DNA Damaged by ROS 
Maintenance of genomic integrity is of paramount importance to the 
ceil, thus DNA damage must be recognised and repaired efficiently . 
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Unrepaired DNA or inaccurate repair of DNA damage can lead to cell death 
or, in long-lived multicellular organism, to the generation of cells with 
tumorigenic potential (Loft and Poulsen, 1996). To counteract deleterious 
alterations of the genetic material, living organisms have evolved a number 
of mechanisms (Rao, 1993; Henle and Linn, 1997). A breif indication of 
the various DNA-repair systems operating in the living world is given in 
Table-5. 
In response to DNA damage most eukaryotic cells arrest at the Gj/S 
S or G2/M cell cycle "check points". These check points prevent cell 
division from occuring until the DNA damage has been repaired and they 
also ensure that damaged DNA is not replicated (Jackson, 1996). 
Objectives of the Present Study 
The review of literature makes it evident that oxidative DNA damage 
is an important carcinogenic factor and also plays a vital role in the 
pathogenesis of inflammatory diseases such as SLE. Human DNA adduct 
formation (Covalent modification of DNA) is a promising biomarker for 
elucidating the molecular epidemiology of these diseases. 
In the present study, human placental DNA was purified free of 
proteins and single stranded regions. The purified DNA was modified with 
hydroxyl radicals (*0H) generated by UV irradiation in presence of 
hydrogen peroxide. Native and ROS modified DNA were characterized by 
UV- and CD-spectroscopy, thermal denaturation studies, sedimentation 
through alkaline sucrose density gradient ultracentrifugation, nuclease SI 
digestibility and hydroxyapatite column chromatography. Base modification 
in ROS-DNA was quantified by DEAE Sephadex A-25 column 
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TABLE - 5 
Various DNA Repair Systems in the Living World* 
Mode of repair Enzymes/proteins implicated 
Reversal of damage 
Photoreativation; demethylation 
Rejoining of single-strand breaks 
Excision repair 
Nucleotide excision repair including 
mismatch repair 
Base excision repair 
Recombinational repair 
DNA-photolyase;0*-methyIguanine-methyltransferase, 
DNA-ligase 
Poly (ADP-ribose)polymerase UV-damage DNA 
specific binding protein;T:G mismatch specific 
binding protein 
dRPase; incision endonucleases;exonuclease (S); 
DNA polymerase(s);DNA-ligase 
DNA-glycosylases; 
AP(apunnic/apyrimidinic) endonucleases; 
exonucleases;DNA-polymerase and ligase 
Rec ABC gene products in E.coli, S' nuclease, 
single-strand binding protein, and other factors/ 
proteins yet to be identified 
From: Rao, K.S. (1993) Genomic Damage and its Repair in Young and Aging Brain. 
Molecular Neurology, 7, 23-48. 
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chromatography. 
Antigenicity of modified human DNA was probed by inducing 
antibodies in experimental animals. ROS-human DNA was found to be 
highly immunogenic as assessed by direct binding ELISA. The specificity 
of induced antibodies was evaluated by competition ELISA and gel 
retardation assay. Direct immunofluorescence of kidney sections from 
rabbits immunized with ROS-human DNA revealed immune complex 
deposition in glomeruli. Furthermore, light microscopic study of renal 
biopsy confirmed glomerulonephritis like condition in kidney of rabbits 
immunized with ROS-human DNA. 
Anti-ROS-human DNA antibodies were used as probes for 
immunochemical detection of oxidative damage in DNA isolated from 
various cancer patients. Alternatively, circulating antibodies in sera of 
cancer and SLE patients were characterized for their binding towards native 
and ROS-human DNA. 
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MATERIALS 
Chemicals 
Human placental DNA, calf thymus DNA, nuclease SI, proteinase K, bovine 
serum albumin, methylated bovine serum albumin, anti-human and anti-rabbit 
IgG alkaline phosphatase conjugates, anti-rabbit-IgG-FITC conjugate, p-
nitrophenyl phosphate, Freund's complete and incomplete adjuvants, ethidium 
bromide, Coomassie Brilliant Blue G 250 and R 250, sodium dodecyl sulphate, 
Tween-20, agarose and hydroxyapatite were purchased from Sigma Chemical 
Company, U.S.A. Synthetic polynucleotides. Protein A-Sepharose CL-4B, DEAE 
Sephadex A-25 and Ficoll 400 were obtained from Pharmacia Fine Chemicals, 
Sweden. EDTA (disodium salt), chloroform, isoamyl alcohol and hydrogen 
peroxide were from Qualigens, India. 
Polystyrene microtitre flat bottom ELISA plates having 96 wells (7 mm 
diameter) were purchased from Nunc, Denmark. Folin-Ciocalteau reagent was 
from Centre for Biochemical Technology, New Delhi. Acrylamide, ammonium 
persulphate, bisacrylamide, N,N,N',N'-tetramethylethylenediamine (TEMED) 
were obtained from Bio-Rad Laboratories, U.S.A. All other chemicals were of 
highest analytical grade available. 
Equipment 
Shimadzu UV-240 spectrophotometer equipped with thermo-programmer 
and controller unit, Jasco J-720 spectropolarimeter equipped with a 
thermostatically controlled cell holder, ELISA microplate reader MR - 600 
(Dynatech, U.S.A.), ELISA microplate washer (Denley, England), ELICO pH 
meter model Ll-IOT, ultraviolet lamp (Vilber Lourmat, France), agarose gel 
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electrophoresis apparatus GNA - 100 and gradient mixer GM-1 (Pharmacia, 
Sweden), Beckman ultracentrifuge, Avanti 30 table top high speed refrigerated 
centrifuge (Beckman, U.S.A.), polyacrylamide gel electrophoresis assembly (Bio-
Rad, U.S.A) and fluorescent microscope (Nikon, Japan) were the major equipment 
used in this study. 
Collect ion of Serum and Blood Samples 
Serum and blood samples were collected from normal human subjects and 
cancer patients with histopathological diagnosis. SLE sera were obtained from 
patients showing high titre anti-DNA antibodies and fulfilling the American 
College of Rheumatology criteria for the diagnosis of SLE (Arnett et al, 1988). 
Sera were decomplemented by heating at 56"C for 30 minutes and stored in 
aliquots at -80"C with 0.1% sodium azide. Lymphocytes were isolated from fresh 
blood by repeated centrifugation at 2000 r p m in red blood cell (RBC) lysing 
solution and stored at -SCC. 
METHODS 
Purification of DNA 
Commercially obtained, highly polymerized human placental DNA and calf 
thymus DNA were purified free of proteins, RNA and single stranded regions as 
described by AH et al. (1985). The DNA (2 mg/ml) was dissolved in 0.1 X SSC 
(15 mM sodium citrate and 150 mM sodium chloride), pH 7.3 and mixed with an 
equal volume of mixture of chloroform - isoamyl alcohol (24:1). The sample 
was extracted in a stoppered measuring cylinder for 1 hour. The aqueous layer 
containing DNA was separated from the organic layer and re-extracted by mixing 
with fresh mixture of chloroform - isoamyl alcohol. The DNA in aqueous layer 
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was precipitated with two volumes of cold absolute ethanol and collected on a 
glass rod. After air drying, the DNA was dissolved in acetate buffer,(30 mM 
each of sodium acetate and zinc chloride), pH 5.0, and treated with nuclease SI 
(150 units/mg DNA) at ST^C for 30 minutes to remove single stranded regions. 
The reaction was stopped by adding one-tenth volume of 200 mM EDTA, pH 
8.0. The nuclease SI treated DNA was extracted twice with mixture of 
chloroform-isoamyl alcohol and finally precipitated with two volumes of cold 
ethanol. The precipitated DNA was dissolved in phosphate buffered saline (PBS) 
(10 mM sodium phosphate containing 150 mM sodium chloride), pH 7.4. 
Determination of DNA Concentration 
The concentration of DNA was determined by the method of Burton (1956). 
(a) Crystallization of diphenylamine 
Diphenylamine (2 gm) was dissolved in 200ml boiling hexane. 
Approximately 0.5 gm of activated animal charcoal was added and filtered through 
Whatman filter paper. The filtrate was kept overnight at 4"C. Diphenylamine 
crystals so obtained, were again filtered to remove hexane and finally dried at 
room temperature. 
(b) Preparation of diphenylamine reagent 
Recrystallized diphenylamine (750 mg) was dissolved in 50 ml glacial acetic 
acid containing 0.75 ml concentrated sulphuric acid. 
(c) Procedure 
One ml of IN perchloric acid was added to 1.0 ml of DNA sample and 
incubated in a thermostat water bath at 70° C for 15 minutes. One hundred 
microlitre of 5.43 mM acetaldehyde was added followed by 2.0 ml of freshly 
34 
prepared diphenylamine reagent. The contents were mixed, incubated at room 
temperature for 16-20 hours and absorbance was recorded at 600 nm. The DNA 
concentration in unknown samples were determined using double stranded 
human DNA as standard . 
Determination of Protein Concentration 
Protein was estimated by the method of Lowry et al. (1951) and Bradford 
(1976). 
Protein estimation by Folin's - phenol reagent 
Protein estimation by this method utilizes alkali (to keep the pH high), 
Cu^'^ions (to chelate proteins) and tartarate (to keep the Cu^'^ions in solution at 
high pH). 
a) Folin - Ciocalteau reagent 
The reagent was obtained commercially and diluted 1:4 with distilled water 
before use. 
b) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as follows: 
(i) Two percent sodium carbonate in 100 mM sodium hydroxide. 
(ii) 0.5 percent copper sulphate in 1.0 percent sodium potassium tartarate. 
The working reagent was prepared fresh before use by mixing components 
(i) and (ii) in the ratio of 50:1. 
c) Procedure 
To l.O ml of protein sample was added 5.0 ml of alkaline copper reagent. 
The samples were allowed to stand at room temperature for 10 minutes. Working 
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Folin-Ciocalteau reagent(l.O ml) was added to the tubes, mixed and incubated 
for 30 minutes at room temperature. The absorbance was recorded at 660 nm . 
The concentration of protein in unknown sample was determined from a standard 
plot constructed by using varying concentrations of bovine serum albumin. 
Protein estimation by dye-binding method 
This assay is based on colour change that occurs when Coomassie Brilliant 
Blue G 250 in acidic medium, binds strongly to protein hydrophobically at 
positively charged groups (Bradford, 1976). In the environment of these 
positively charged groups, protonation is suppressed and a blue colour is observed 
(I =595 nm). 
^ max •' 
(a) Dye preparation 
One hundred mg Coomassie Brilliant Blue G 250 was dissolved in 50 ml 
of 95% ethanol. To this solution was added 100 ml of 85% (v/v) orthophosphoric 
acid. The resulting solution was diluted to a final volume of 1 litre. 
(b) Protein assay 
To 1.0 ml solution containing 10-100 (xg protein, was added 5 ml of dye 
solution and contents were mixed by vortexing. The absorbance was taken at 
595 nm after 5 minutes, against a reagent blank. 
Modification of Human Placental DNA by Reactive 
Oxygen Species 
Aqueous solution of native human placental DNA (0.15 mM bp) in PBS, 
pH 7.4 were irradiated under 254 nm light in the presence of 100 fold excess of 
hydrogen peroxide (15.1 mM), for 30 minutes at room temperature. Excess of 
hydrogen peroxide was removed by extensive dialysis against PBS, pH 7.4. Native 
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human DNA samples exposed to hydrogen peroxide or UV light alone served as 
controls. 
Spectroscopic Analysis 
(a) Ultraviolet - Spectra 
The ultraviolet (UV) spectra of modified and unmodified human DNA were 
recorded in the wavelength range of 200 nm to 400 nm on a Shimadzu UV - 240 
spectrophotometer. 
(b) Circular Dichroism-Spectra 
The circular dichroism (CD) spectra were taken on a Jasco J - 720 
spectropolarimeter using quartz cell of 1 cm path length. CD - spectra of both 
native and ROS-human DNA were recorded in the wavelength range of 200 nm 
to 350 nm. Scans were recorded at 0.2 nm intervals. The concentration of DNA 
was 151 i^ M base pair. Molar ellipticity [ 0 ] were calculated in terms of the base 
pair concentration according to following equation. 
8 
[ 9 ] = 
10 cl 
Where, 9 = Measured ellipticity (mdeg) 
c •= Molar concentration of DNA. 
1 = Path lenght in cm. 
Absorption - Temperature Scan 
Thermal denaturation analysis of nucleic acids was performed in order to 
ascertain the degree of modification incurred on the nucleic acids by determining 
mid-point melting temperature (T ). Native and ROS - human DNA as well as 
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its controls were subjected to heat denaturation in a Shimadzu L/V-240 
spectrophotometer coupled with a temperature programmer and controller 
assembly (Hasan and Ali, 1990). All the samples were melted from SO^C to 95°C, 
at a rate of l.S^C / minute, after 10 minutes equilibration at 30°C. The change in 
absorbance at 260 nm was recorded with increasing temperature. Percent 
denaturation was calculated as follows: 
A ^ - Ajg 
Percent denaturation = x 100 
A - A,„ 
max 30 
Where, Aj. = Absorbance at a temperature T"C 
A = Final maximum absorbance on the completion of 
max * 
denaturation 
A3Q = Initial absorbance at 30°C. 
Hydroxyapatite Column Chromatography 
Hydroxyapatite column chromatography was employed to differentiate 
nucleic acids endowed with different secondary structures. Native, heat denatured 
and ROS modified human DNA samples (in 10 mM Na-phosphate buffer, pH 6.8) 
were chromatographed on hydroxyapati te column as described by Dardalhon 
and Averbeck (1988). Batch elution was carried out with 125 mM and 250 mM 
Na-K-phosphate buffer, pH 6.8 at a flow rate of 15 ml/hour, fractions of 3 ml 
were collected and absorbance monitored at 260 nm. 
Detection of Strand Breaks 
The damage to DNA induced by ROS was ascertained by alkaline sucrose 
density gradient ultracentrifugation and nuclease SI digestion. 
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(a) Alkaline Sucrose Density Gradient Ultracentrifugation 
Native and ROS - human DNA (0.2 ml of 100 jig/ml) were treated with an 
equal volume of 0.2 N NaOH. After 10 minutes to allow denaturation of DNA, 
0.4 ml sample was layered on top of a linear 4.6 ml alkaline sucrose gradient (5-
20% sucrose containing 800 mM NaCl, 200 mM NaOH and 10 mM EDTA) (Ali 
and Sauerbier, 1978). The gradients were centrifuged at 30,000 rpm for 1 hour 
at room temperature in swinging bucket rotor of Beckman ultracentrifuge. The 
bottom of the tubes were pierced and six drop fractions collected were diluted 
to about 0.5 ml with distilled water and their absorbance recorded at 260 nm. 
(b) Nuclease SI Digestibility 
Native and ROS-human DNA were characterized by nuclease SI 
digestibility (Matsuo and Ross, 1987). One microgram each of native and 
modified DNA in acetate buffer (30 mM each of sodium acetate and zinc chloride, 
pH 5.0) were treated with nuclease SI (20 units / |ig DNA) for 30 minutes at 
37°C. The reaction was stopped by adding one tenth volume of 200 mM EDTA, 
pH 8.0. The nuclease SI digested samples and control samples were subjected to 
agarose gel electrophoresis. 
(i) Gel preparation 
Agarose (1%) in TAE buffer (40 mM Tris-acetate, pH 8.0 containing 2 
mM EDTA) was dissolved by heating. The solution was cooled to about 50° C 
and then poured into the gel tray and allowed to solidify at room temperature. 
(ii) Sample preparation and loading 
Native and modified DNA samples treated with nuclease SI were mixed 
with one-tenth volume of sample buffer (0.125% bromphenol blue, 30%) Ficoll 
400, 500 mM EDTA in lOX electrophoresis buffer). The samples were loaded in 
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the wells and electrophoresed for 2 hours at 30 mA. The gels were stained with 
ethidium bromide (0.5 |.ig/ml), viewed by illumination under UV light and 
photographed. 
Separation and Quantitation of DNA Bases 
The separation and quantitation of bases in native and ROS-human DNA 
was carried out according to Hasan and Ali (1990). 
(a) Acid hydrolysis of DNA samples 
Native and ROS-human DNA samples were treated with 70% perchloric 
acid. The samples were heated at 100° C for Ihour to release the bases. The 
hydrolyzate was neutralized and the bases were separated on DEAE Sephadex 
A-25 column. 
(b) DEAE Sephadex A-25 column chromatography 
The swollen ion-exchanger was mixed with equilibrating buffer (ImM Tris-
HCl, pH 7.6) and packed in a column (40 cm x 0.75 cm). The column was 
equilibrated with the same buffer, hundred microgram sample was applied onto 
the column and eluted with a linear gradient of 1-20 mM Tris-HCl, pH 7.6, at a 
flow rate of 40 ml/hr. Three ml fractions were collected and absorbance read at 
260 nm. The control experiments were carried out with individual bases and 
hydrolyzed native DNA, their elution profile served as standard to locate the 
pattern of unmodified bases. 
Immunization Schedule 
Native and ROS-human DNA (100 }.ig each) were complexed with an equal 
amount (w/w) of methylated BSA and emulsified with an equal volume of 
complete Freund's adjuvant and injected intramuscularly in female rabbits. 
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Subsequent injections were given in incomplete Freund's adjuvant. Each animal 
received a total of 500 //g of antigen in the course of five injections. Blood was 
collected by cardiac puncture, serum was separated and decomplemented by 
heating at 56° C for 30 minutes. Pre-immune serum was collected prior to 
immunization. The sera were stored in small aliquots at -SCC with 0.1% sodium 
azide as preservative. 
Direct Immunofluorescence on Kidney Section 
Kidney was ablated from immunized rabbits and cut into 5 [im thick 
sections with the help of a cryostat at -30° C . The sections were fixed with acetone 
on a glass slide, and incubated with anti-rabbit IgG fluorescein isothiocyanate 
conjugate (1:100 diluted) for 30 minutes. After washing thrice with PBS, pH 
7.4, the sections were mounted with 50% glycerol and viewed under a fluorescent 
microscope. 
Tissue Processing for Light Microscopy 
Slices of kidney from rabbits immunized with native and ROS-human 
DNA were fixed in 10% formalin, dehydrated with increasing strength of ethanol 
(50%, 70%, 90%, and 2 changes of absolute ethanol), cleared in xylene and wax-
impregnated before finally casting and blocking. Paraffin blocks of the kidney 
pieces were fixed to the block holder and sections (approximately 5\im thick) 
were cut. The sections were dewaxed with xylene and hydrated using descending 
grades of alcohol (absolute, 90%, 70%, 50%, and 30%). The sections were then 
stained with haematoxylin (nuclei stain) and eosin (cytoplasm stain). After 
staining, the sections were once again dehydrated with ascending grades of 
alcohol (70%, 90% and 100%). Finally the sections were cleared with xylene (2 
changes) and mounted in DPX for microscopic observations. 
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Isolation of IgG by Protein A-Sepharose CL-4B Column 
Serum IgG was isolated by affinity chromatography on Protein A-Sepharose 
CL-4B column. Serum (0.5 ml) diluted with, an equal volume of PBS, pH 7.4 was 
applied to the column (0.9 cm x 15 cm) equilibrated with the same buffer. The 
wash through was recycled 2-3 times. Unbound IgG was removed by extensive 
washing with PBS, pH 7.4. The bound IgG was eluted with 0.58% acetic acid in 
0.85% sodium chloride (Goding, 1976). Three ml fractions were collected in a 
measuring cylinder already containing 1ml of IM Tris-HCl, pH 8.5 and absorbance 
was recorded at 251 nm and 278 nm. The IgG concentration was determined 
considering 1.4 0.D2gQ=1.0 mg mammalian IgG / ml. The isolated IgG was then 
dialyzed against PBS, pH 7.4 and stored at - 80°C with 0.1% sodium azide. 
Polyacrylamide Gel Electrophoresis For Proteins 
Polyacrylamide slab gel electrophoresis was performed under denaturing 
conditions as described by Laemmli (1970). The following stock solution were 
prepared. 
(i) Acrylamide-bisacrylamide (30:0,8) 
A stock solution was prepared by dissolving 30 gm of acrylamide and 0.8 
gm bisacrylamide in distilled water to a final volume of 100 ml. 
(ii) Resolving gel buffer 
A stock solution was prepared by dissolving 36.3 gm Tris base in 48.0 ml 
of IN HCl. The contents were mixed, pH adjusted to 8.8 and the final volume 
brought to 100 ml with distilled water. 
(Hi) Stacking gel buffer 
6.05 gm Tris was dissolved in 40 mi distilled water, pH titrated to pH 6.8 
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with IN HCl and the final volume adjusted to 100 ml with distilled water. 
(iv) Electrode buffer 
3.03 gm Tris, 14.4 gm glycine and 1.0 gm SDS were dissolved in distilled 
water, pH adjusted to 8.3 and final volume made up to one litre. 
(v) Procedure 
Glass plates, separated by 1.5 mm thick spacer were sealed with 1% 
agarose, the resolving gel mixture was prepared by mixing the components in 
the appropriate volume and poured into the space between the glass plates leaving 
sufficient space at the top for the stacking gel. After the polymerization of 
separating gel, stacking gel mixture was poured and allowed to solidify. Protein 
samples containing 10% glycerol and 0.002% bromophenol blue were applied 
and electrophoresis was carried out at 60V for 6-8 hours. The gel was stained 
with 0.1% Coomassie Brilliant Blue R 250 (in 25% isopropanol and 10% glacial 
acetic acid). Destaining was carried out in a mixture of 10% acetic acid and \0% 
methanol. 
Recipe for 7.5% SDS - PAGE 
Solutions Stacking gel Resolving gel 
Acrylamide-bisacrylamide 1.25 ml 7.5 ml 
Stacking gel buffer 2.50 ml 
Resolving gel buffer - 3.75 ml 
Distilled water 5.64 ml 16.95 ml 
10% SDS 0.10 ml 0.30 ml 
1.5% Ammonium persulphate 0.50 ml 1.50 ml 
TEMED 0.75 ml 15 \x\ 
43 
Detection and Quantitation of Antibodies 
Sera was tested for ant ibodies by immunodiffusion, counter-
immunoelectrophoresis,gel retardation and enzyme linked immunosorbent 
assay. 
(a) I m m u n o d i f f u s i o n 
Immunodiffusion (ID) was carried out by Ouchter lony double 
diffusion system. Six ml of 0.4% molten agarose in PBS containing 0 .1% 
sodium azide was poured on to glass petridishes and allowed to solidify 
at room temperature. Wells of 5 mm diameter were cut into hardened gel 
and appropriate concentration of antigen and antibody was placed in the 
wells. The petridishes were allowed to stand in a moist chamber at room 
temperature for 48-72 hrs. The gels were washed with 5% sodium citrate 
to remove non-specific precipitin lines. The result was analyzed visually. 
(b) Counter immunoelectrophoresis 
Counterimmunoelectrophoresis (CIE) was performed by the method 
of Kurata and Tan (1976) using 0.6% molten agarose solution in 25 mM 
barbital buffer, pH 8.4 containing 0.1% sodium azide. Molten agarose was 
poured on to 2.5 mm thick glass slides (7.5 cm x 2.5 cm) and allowed to 
harden at room temperature and then at 4°C. Wells 3 mm in diameter were 
punched and loaded with antigen and antibodies (in anodal and cathodal 
wells, respectively). Electrophoresis was performed for 30 min in 50 mM 
barbital buffer, pH 8.4 with a current of 3-4 mA per slide. Non-specific 
precipitin lines were removed with 5% sodium citrate. 
(c) Enzyme Linked Immunosorbent Assay (ELISA) 
The antibodies were detected and quantitated by ELISA on flat bottom 96 
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well microtitre plates according to the method of Aotsuka et a/.(1979) with slight 
modification. 
(i) Buffers and reagents 
Tris buffered saline (TBS) 
10 mM Tris, 150 mM NaCl, pH 7.4 
Tris buffered saline - Tween 20 (TBS - T) 
20 mM Tris, 144 mM NaCl, 2.68 mM KCl, pH 7.4, containing 500 |.il Tween 
20/L. 
Carbonate - bicarbonate buffer 
15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6, containing 
2 mM magnesium chloride. 
Substrate 
500 i^ g p-nitrophenyl phosphate (p-NPP) / ml of carbonate-bicarbonate buffer, 
pH9.6. 
(ii) Procedure 
The test wells of microtiter plates were coated with 100 |j,l of antigen (2.5 
//g/ml in TBS) for 2 hours at 37° C and overnight at 4°C. The antigen coated 
wells were washed three times with TBS-T to remove unbound antigen. 
Unoccupied sites in the wells were blocked with 150 ju\ of 1.5% BSA in TBS for 
5 hours at room temperature. The plates were washed once with TBS - T and 
antibody (100 |il of 1:100 dilution in TBS/ well) to be tested, were absorbed for 
2 hours at room temperature and overnight at 4''C. The unbound antibody was 
washed off 4 times using TBS-T. An appropriate anti-immunoglobulin alkaline 
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phosphatase conjugate (100|il of 1:2000 dilution) was added to each well. After 
incubation at 37" C for 2 hours, the plates were washed four times with TBS-T 
and three times with distilled water and developed using p-nitrophenyl phosphate 
substrate. The absorbance was recorded at 410 nm on an automatic microplate 
reader after proper colour development. Each sample was run in duplicate. The 
control wells were treated similarly but were devoid of antigen. Results were 
expressed as a mean of A - A . . . 
r test control 
d) Competition ELISA 
The antigenic specificity of the antibodies was determined by competition 
ELISA (Hasan etal., 1991). Varying amounts (0-20|ig/ml) of inhibitors were mixed 
with 100 \x\ of 1:100 diluted antiserum or 60 |J.g/ml IgG. The mixture was incubated 
at room temperature for 2 hours and overnight at 4°C. The immune complex thus 
formed was coated in the wells and direct binding ELISA was performed. Percent 
inhibition was calculated using the formula. 
inhibi ted 
Percent inhibition = [ 1- ] x 100 
uninhibited 
A . , ., . . = Absorbance at 20 j^g/ml inhibitor cocentration 
A . .... , - Absorbance at zero inhibitor concentration 
uninhibited 
(c) Gel Retardation Assay 
For the visual detection of antigen-antibody interaction and immune 
complex formation, gel retardation assay was performed (Sanford et al., 1988). 
A constant amount of antigen (native and ROS-human DNA) one jig each was 
incubated with varying amounts (0-50 |j,g) of IgG in PBS, pH 7.4 for 2 hours at 
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37"C and overnight at 4°C. One tenth volume of 's top mix' dye (0.25% xylene 
cyanole and 15% Ficoll 400) was added to the samples and electrophoresed on 
1% agarose for 2 hours at 30 mA in 40 mM Tris-acetate buffer, pH 7.9. The gels 
were stained with ethidium bromide (0.5 |ag/ml), visualized under UV light and 
photographed. 
Isolation of DNA from Human Lymphocytes 
Blood samples were collected in EDTA from different cancer patients and 
normal healthy individuals. Lymphocytes were harvested from blood by repeated 
centrifugation at 2000 rpm in ice cold RBC lysing solution (155 mM NH^Cl, 10 
mM NaHCOj, 0.1 mM EDTA, pH 7.4). 
DNA was isolated from lymphocytes essentially as described by Baas et 
al. (1984). Lymphocytes were suspended in lymphocyte lysis buffer (10 mM Tris, 
2 mM EDTA, 400 mM NaCl, containing 1% SDS and Img/ml proteinase K), 
incubated at 50" C for 1 hour and overnight at 37" C with constant shaking. An 
equal volume of chloroform: isoamyl alcohol (24:1) was added and the mixture 
was shaken for 20 minutes. The phases were separated by centrifugation. Aqueous 
layer containing DNA was removed and mixed gently with 2 volumes of ice cold absolute 
ethanol. After 18 hours incubation at -20" C DNA was collected by centrifugation at 
5000 rpm for 5 minutes at 4"C. The pellet of precipitated DNA obtained was washed 
with 70% (v/v) ethanol. After air drying the DNA was dissolved in PBS, pH 7.4. 
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Modification of Human Placental DNA by Hydroxyl Radical 
Commercially available human placental DNA, was purified free of 
proteins, RNA and single stranded regions. The solution of purified hu-
man DNA was modified with hydroxyl radical (OH) generated by UV ir-
radiation (254 nm) in presence of hydrogen peroxide. The modified samples 
were dialyzed extensively against PBS, pH 7.4 to remove excess hydrogen 
peroxide. 
Characterization of Modified Human DNA 
Ultraviolet Absorption Spectral Studies 
The ultraviolet (UV) absorption spectra of ROS-human DNA showed 
a decrease in absorbance over the entire UV range, with a marked 
hypochromicity (22.5%) at 260 nm. The corresponding controls i.e. UV 
irradiated human DNA and human DNA treated with hydrogen peroxide 
alone showed no appreciable change in their UV absorption characteris-
tics. The UV spectra of native human DNA, ROS-human DNA and its cor-
responding controls are shown in Fig. 2. 
Circular Dichroism of Native and Modified Human DNA 
The circular dichroism (CD) spectra of native and ROS-human DNA 
showed characteristic changes in ellipticity (Fig. 3). Native human DNA 
showed a ^ . at 245 nm and X at 277.3 nm, with a broad peak. ROS-
mm max ' ~ 
human DNA showed negative peak at 246.6 nm and positive peak at 279.5 
nm followed by a shoulder at 242.4 nm and a complete reversal of peak 
broadness at 273.14 nm. 
ROS-human DNA when compared with native human DNA showed a 
change in ellipticity from -6.2 mdeg to -17.0 mdeg at the negative peak 
48 
200 300 
WAVELENGTH (nm) 
AOO 
Fig.2. Ultraviolet absorption spectra of native human DNA ( )UV-
irradiated human DNA ( ), human DNA-hydrogen peroxide 
complex ( ) and ROS-human DNA ( ). 
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Fig.3. Circular dichroism spectra of native human DNA ( — )and ROS-
human DNA ( ). 
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and from 3.1 mdeg to 12.7 mdeg for positive peak. The CD spectral analy-
sis indicates 75% decrease in ellipticity of native human DNA following 
ROS modification. 
Thermal Denaturation of Native and Modified Human DNA 
Thermally induced transitions were measured spectrophotometrically 
at 260 nm by heating nucleic acid samples at a rate of 1.5°C/min. Melting 
profile of modified and unmodified human DNA were analysed between 
the temperature range 30°C to 95°C. The increase in absorbance at 260 nm 
was taken as a measure of helix denaturation. The process was character-
ized by determining the percent DNA in denaturing state as the tempera-
ture increased and by computing the melting temperature (T^). T^ values 
of native human DNA, UV irradiated human DNA, DNA-H2O2 complex and 
ROS-human DNA were found to be 86.5"C, 85.5°C, 85°C and 74°C respec-
tively (Table. 6). The results indicate a significant decrease (14.4%) in T^ 
value of ROS-human DNA as compared to the native conformer (Fig. 4). 
The decrease in T^ value for UV irradiated and H202-human DNA complex 
was only 1.15% and 1.73% respectively. The lower T^ value of ROS-hu-
man DNA indicates structural alteration in DNA which occur following 
generation of single strand breaks. 
The physicochemical characteristics of native and ROS-human DNA 
have been summarized in Table 7. 
Hydroxyapatite Column Chromatography 
Nucleic acids with different secondary structures have more affinity 
for hydroxyapatite than flexible, disordered polymers. To ascertain the 
double strandedness of ROS-human DNA, native and modified human DNA 
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TABLE - 6 
Thermal Denaturation Characteristics of Human DNA 
Onset of duplex Melting temperature Percent 
melting," C (T„)»"C decrease 
in T 
Native human DNA 79 
UV irradiated DNA 79 
DNA-H^O^ complex 83 
ROS-human DNA 35 
86.5 
85.5 
85.0 
74.0 
-
1.15 
1.73 
14.45 
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TABLE - 7 
Physicochemical Characteristics of Native and ROS-human DNA 
Under Identical Experimental Conditions. 
Parameters Native human DNA ROS-human DNA 
Absorbance ratio (A2gyA2gp) 1.95 1.57 
Percent hyperchromicity 25.8 26,5 
at95°C 
Melting temperature (TJ/'C 86.5 74.0 
Onset of duplex melting,°C 80.0 35.0 
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samples were fractionated on hydroxyapatite column. 
The DNA samples (native, heat denatured and ROS modified) in lOmM 
sodium phosphate buffer, pH 6.8, were applied to hydroxyapatite column, 
equlibrated with the same buffer. After washing the unbound material, batch 
elution was carried out with 125 mM and 250 mM Na-K-phosphate buffer, 
pH 6.8. Three ml fractions were collected and absorbance was monitored 
at 260 nm. The chromatographic profile (Fig.5), showed elution of double 
stranded DNA with 250 mM Na-K-phosphate buffer, pH 6.8, whereas heat 
denatured DNA eluted at 125 mM Na-K-phosphate buffer, pH 6.8. In con-
trast, the elution profile of ROS-human DNA exhibited two distinct peaks, 
a minor and a major peak eluting with 125 mM and 250 mM Na-K-phos-
phate buffer, pH 6.8 respectively, accompanied by a slight shift in peak 
position. 
Nuclease SI Digestibility 
Native and ROS-human DNA were digested with nuclease SI (20 
units/|ig DNA) for 30 minutes and electrophoresed on 1% agarose gel. The 
controls were native and ROS-human DNA untreated with nuclease SI. 
ROS-human DNA showed decrease in fluorescence intensity following 
nuclease SI digestion. On the other hand nuclease SI treated and untreated 
native human DNA showed almost identical electrophoretic migration pat-
tern and fluorescence intensity (Fig. 6). 
Electrophoretic Pattern 
The agarose gel electrophoretic pattern of ROS modified human DNA 
is shown in Fig. 7. Native, UV irradiated and H2O2 treated human DNA 
served as corresponding controls. The nucleic acid samples were electro-
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1 Z 3 M 
- Fig.6. Nuclease SI sensitivity of native and ROS-human DNA Lanes: 
(1) native human DNA (2) nuclease SI treated native human 
DNA (3) ROS-human DNA and (4) nuclease SI treated ROS-
human DNA. 
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1 Z 3 W 
Fig.7. Agarose gel electrophoresis of native and ROS modified human 
DNA. Lanes: (1) native human DNA (2) human DNA-Hydrogen 
peroxide complex (3) UV-irradiated human DNA and (4) ROS-
human DNA. 
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phoresed on 1% agarose gel for 2 hrs. at 30 mA. The results indicated that 
ROS-human DNA migrated in form of a short stretch away from point of 
application whereas native human DNA showed a stretch starting from the 
point of sample application. The UV irradiated DNA and H2O2-DNA com-
plex showed a pattern similar to that of native human DNA with a slight 
decrease in fluorescence intensity. The results indicate structural alter-
ations in DNA following attack by ROS. 
Alkaline Sucrose Density Gradient Ultracentrifugation 
Native and ROS-human DNA were subjected to sucrose density gra-
dient ultracentrifugation under alkaline conditions, to detect single strand 
breaks. Nucleic acid samples were denatured by addition of 0.2N NaOH, 
layered on top of a 5-20% linear alkaline sucrose gradient and sedimented 
at 30,000 r p m for one hour. The bottom of the tubes were pierced and 6 
drop fractions collected were diluted to 0.5 ml with distilled water. Ab-
sorbance of each fraction was monitored at 260 nm and plotted against 
respective fraction numbers (Fig. 8). Native human DNA banded as a sharp, 
symmetrical peak while ROS-human DNA treated under identical condi-
tions showed a broader peak. The altered profile of ROS-human DNA in-
dicates presence of single stranded regions and hence a decrease in mo-
lecular weight. 
Modification of Nitrogenous Bases in DNA by ROS 
In order to separate and quantify the modification of bases, ROS-
human DNA solution was subjected to acid hydrolysis. The neutralized 
hydrolyzate was applied to DEAE Sephadex A-25 column and eluted with 
a linear gradient of 1-20 mM Tris-HCl buffer, pH 7.6. Control experiments 
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Fig.8. Alkaline sucrose density gradient ultracentrifugation of native 
human DNA ( O ) and ROS-human DNA ( A ). The arrow on top 
shows the direction of the gradient. 
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were carried out by passing individual standard bases (Fig. 9) and acid 
hydrolyzed native human DNA (Fig. 10) through same column. 
Elution profile of native DNA was similar to that obtained with in-
dividual bases. Peaks 1, 2, 3, and 4 in Fig. 10, represent cytosine, thymine, 
adenine and guanine respectively. Elution profile of ROS-human DNA 
showed the formation of additional base products (Fig. 11). The base prod-
ucts were identified by comparing the chromatographic pattern with that 
of standard bases. In the elution profile of ROS-human DNA the first and 
second peak correspond to unmodified and modified cytosine, third and 
fourth peak correspond to unmodified and modified thymine, fifth and sixth 
peak correspond to unmodified and modified adenine, while seventh and 
eighth peak represent unmodified and modified guanine respectively. The 
extent of modification of each base was calculated by measuring the peak 
area and was found to be 55.5% for guanine, 33.3% for thymine, 30% for 
cytosine and 16% for adenine (Table 8). 
Antigenicity of Modified Human DNA 
The antigenicity of modified human DNA was determined by induc-
ing antibodies in rabbits. The antigenic specificity of the induced anti-
bodies was assayed by direct binding and competition ELISA. The binding 
of immune IgG to the immunogen and native human DNA was further probed 
by band shift assay. Rabbits immunized against native, UV irradiated and 
H2O2 treated human DNA served as controls. 
Antibodies Against ROS-Human DNA 
The antibodies induced in response to ROS-human DNA were found 
to be non-precipi tat ing as assessed by immunodiffusion and 
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Fig.9. Elution profile of standard individual DNA bases on a DEAE 
Sephadex A-25 column. The standard bases chromatographed 
were (a) cytosine, (b) thymine, (c) adenine and(d) guanine. 
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TABLE - 8 
Modification of Nitrogenous Bases in Human DNA Exposed to ROS 
Nitrogenous base Percent modification 
Cytosine 30.0 
Thymine 33.3 
Adenine 16.0 
Guanine 55.5 
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counterimmunoelectrophoresis. The anti-serum showed a high titre 
(> 1:12800) when tested by direct binding ELISA (Fig. 12). Pre-immune 
sera served as negative control, did not show any appreciable binding to 
ROS-human DNA (Fig. 12). The direct binding ELISA of anti-serum from 
rabbits immunized with native, UV irradiated and H^O^ treated human DNA, 
showed negligible binding to their respective immunogens (Fig. 13). 
The specificity of anti-ROS human DNA antibodies for epitopes on 
immunogen was evaluated by competition ELISA. A maximum of 81% in-
hibition in antibody activity was obtained at an immunogen concentration 
of 20 |ig/ml. The concentration of competitor required for 50% inhibition 
was 6 |ag/ml (Fig. 14). 
Purification and Binding Characteristics of Immune IgG 
Immunoglobulin G was isolated from pre-immune and immune se-
rum, of rabbits immunized with ROS-human DNA, by affinity chromatog-
raphy on a protein A-Sepharose CL-4B column (Fig. 15). The purity of 
IgG was evaluated by SDS-polyacrylamide gel electrophoresis in absence 
of a reducing agent. The purified IgG migrated as a single band upon elec-
trophoresis (Fig. 15 inset). Direct binding ELISA of the purified IgG 
showed high reactivity with the immunogen (Fig. 16). Preimmune IgG as 
negative control showed negligible binding to the immunogen (Fig. 16). 
Antigenic Specificity of Anti-ROS-human DNA-IgG 
The anti-ROS human DNA-IgG exhibited a broad spectrum of cross 
reactivity as observed by its binding to various nucleic acids, synthetic 
polynucleotides and nuclear protein antigens. A maximum of 86% inhibi-
tion was obtained with immunogen as an inhibitor (Fig. 17). In order to 
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inhibit 50% antibody activity, 0.1 |ig/ml of ROS-human DNA was required. 
Native and heat denatured human DNA inhibited the binding of immune 
IgG to ROS-human DNA by a maximum inhibition of 42% and 57% re-
spectively (Fig. 17). Fifty percent inhibition for heat denatured human DNA 
was achieved at 7.0 ^ig/ml. 
Native and ROS-calf thymus DNA showed a maximum inhibition of 
28% and 64% respectively (Fig. 17). To achieve 50% inhibition 5.0 [ig/ml 
of ROS-calf thymus DNA was required. Total RNA from buffalo thymus 
and its ROS modified form showed maximum inhibition of 40% and 74% 
respectively. 8 |ig/ml of ROS-RNA was required to achieve 50% inhibition 
(Fig. 18). Z-DNA inhibited antibody activity by only 5.3% whereas super-
oxide modified DNA showed 26.2% inhibition at 20 |ig/ml (Fig.l8). Native 
and ROS-mitochondrial DNA showed maximum inhibition of 20% and 35% 
respectively (Fig. 18). 
The synthetic nucleic acid polymers such as poly (dG-dC) and poly 
(rG)-poly (dG), when used as inhibitors of antibody activity, showed maxi-
mum inhibitions of 24% and 40% respectively (Fig. 19). The polymers poly 
(G) and ROS-poly (G) inhibited antibody activity by 23% and 28% respec-
tively (Fig. 19). Nuclear proteins such as histones and ribonucleoprotein 
(RNP) inhibited antibody activity by 41.9% and 64.4% respectively. 4.0 
fig/ml RNP was required to achieve 50% inhibition (Fig. 20). 
Cardiolipin and chondriatin sulphate showed maximum inhibition of 
65.3% and 46.8% respectively. 50% inhibition in antibody binding was 
achieved by cardiolipin at a concentration of 7.0 |ig/ml (Fig. 20). Table 9 
summarizes the results of inhibition of anti-ROS human DNA-IgG binding 
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Fig. 18. Inhibition of anti-ROS-human DNA-IgG binding to ROS-human 
DNA. The competitors were O^-DNA ( O ), Z-DNA ( A ), 
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TABLE-9 
Antigenic Specificity of Anti-ROS-human DNA-lgG 
Inhibitor 
ROS-human DNA 
Native human DNA 
ss human DNA 
Maximum percent 
inhibition at 
20 //g/ml 
Native calf thymus DNA 
ROS-calf thymus DNA 
O^-DNA 
Z-RNA 
Native RNA 
ROS-RNA 
Native-mt DNA 
ROS-mt DNA 
Poly (dG-dC) 
Native poly (G) 
ROS-poly (G) 
Poly (rG)-poly (dG) 
Histone 
Ribonucleoprotein 
Cardiolipin 
Chondriatin sulphate 
86.0 
42.0 
57.0 
28.0 
64.0 
26.2 
5.3 
40.0 
74.0 
20.0 
35.0 
24.0 
23.0 
28.0 
10.0 
41.9 
64.4 
65.3 
46.8 
Inhibitor concentration 
for 50% inhibition 
(//g/ml) 
0.1 
* 
7.0 
* 
5.0 
* 
* 
* 
8.0 
* 
* 
* 
* 
* 
* 
* 
4.0 
7.0 
* 
Percent relative 
affinity 
100.0 
-
1.4 
-
2.0 
-
-
-
1.25 
-
-
-
-
-
-
-
2.5 
1.4 
-
* 50% inhibition not achieved 
The microtitre plates were coated with ROS-human DNA (2.5 [ig/ml) 
II 
to ROS-human DNA by various competitors by inhibition ELISA. The rela-
tive binding affinity of immune IgG with various inhibitors has also been 
calculated. 
Band Shift Assay with Immune IgG 
The binding of anti-ROS-human DNA-IgG to native and ROS-human 
DNA was further ascertained by band shift assay. This assay involves vi-
sual detection of antigen-antibody interaction (Fig. 21a & b). A constant 
amount (Ifig) of native and ROS-human DNA were incubated with varying 
amounts of immune IgG (0 to 60 |ig) for 2 hrs. at 37°C and overnight at 
4°C. The resulting immune complexes were electrophoresed on 1% agar-
ose for 2 hrs at 30 mA. It is evident that as the amount of IgG increased 
from 0 to 60 ng there was an increase in formation of high molecular weight 
immune complexes, which resulted in retarded mobility. 
Immunofluorescence Study on Kidney Sections 
The kidney sections from the rabbits immunized with ROS-human 
DNA exhibited fluorescence thus indicating deposition of immune com-
plexes in the glomeruli (Fig. 22a). However, the kidney sections from rab-
bits immunized with native human DNA and processed under identical con-
ditions showed no fluorescence, indicating absence of immune complex 
deposition (Fig. 22b). 
Light Microscopic Study of Kidney Sections 
The kidney sections of immunized rabbits were assessed histologi-
cally. The rabbits immunized with native human DNA showed a normal 
morphology in the kidney (Fig. 23-25) whereas rabbits immunized with 
ROS-human DNA revealed hypercellular^.c'djijested.glomeruli with thick-
/ r \ \ 
, ( Ace. No '-.; 
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Fig.21. Band shift assay of anti-ROS-human DNA-IgG binding to (a) 
native human DNA and (b) ROS-human DNA. Native and ROS-
human DNA (1 fig each) were incubated with 30, 40, 50, 60 jig 
of IgG for 2 hrs. at 37°C and overnight at 4°C. Electrophoresis 
was performed on 1% agarose gel for 2 hrs. at 30 mA. Lane 1 
contains native or ROS-human DNA while lanes 2,3, 4 and 5 
contain native and ROS-human DNA with increasing 
concentrations of immune IgG. 
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Fig.22. Immunofluorescence study for the detection of immune 
complexes in kidney glomeruli of rabbit immunized with (a) ROS-
human DNA and (b) native human DNA. 
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Fig.23. Microphotograph. Kidney from control rabbit immunized with 
native human DNA. H&E stain , X 250. Section shows normal 
morphology of glomeruli, showing capillary tuft, Bowman's 
capsule and tubules lined with cuboidal cells with granular 
I cytoplasm. 
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Fig.24. Microphotograph. Kidney from control rabbit immunized with 
native human DNA, H&E stain, X 500. Section shows high 
power view of normal glomerulus. The capillary tuft shows 
normal number of endothelial and mesengial nuclei. The space 
in the Bowman's capsule is clear and the basement membrane 
is not thickned. 
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Fig.25. Microphotograph. Kidney from control rabbit immunized with 
native human DNA, H&E stain, X 500. Section shows high 
power view of tubules lined with cuboidal epithelium having 
central vesicular nucleus, granular cytoplasm and clear lumen. 
i 
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ened basement membrane (Fig. 26-28). 
I 
Preferential Binding Characteristics of Circulating Human 
Anti-DNA Autoantibodies to ROS-human DNA 
In order to determine the antigenicity of hydroxyl radical modified 
human DNA, binding of twelve SLE sera (1:100 dilution) to native calf 
thymus DNA , native human DNA and ROS-human DNA were assayed by 
direct binding ELISA (Fig. 29). All the sera tested showed greater reactiv-
ity to ROS-human DNA followed by native human DNA and native calf 
thymus DNA. Thus human DNA (both native and ROS modified form) was 
found to be more antigenic than native calf thymus DNA. 
( 
Antigenic Specificity of SLE Autoantibodies 
' The specificity of each SLE sera for native and ROS-human DNA 
was evaluated by competitive binding assay. The antibody was incubated 
with increasing concentrations (0-20 (ig/ml) of inhibitors (native or ROS-
human DNA) and then assayed for residual binding to double stranded 
human DNA. Out of the twelve SLE sera tested, ROS-human DNA showed 
higher degree of recognition to six sera and inhibited their activity to a 
maximum of 67%. Inhibitor concentration required for 50% inhibition was 
12 |ig/ml (Fig.30b-32b). However, native human DNA was found to be less 
reactive for the same serum samples and only three samples could achieve 
a maximum of 50% inhibition at 20 |ig/ml (Fig.30a-32b). 
,• The results of this study, summarized in Tables 10 and 11 show ROS-
human DNA to be a better inhibitor for all the twelve SLE sera tested. 
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rig.26. Microphotograph. Kidney from experimental rabbit immnized 
I with ROS-human DNA, H&E stain, X250. Section shows larger 
I glomerular capillary tuft with increased number of nuclei 
showing proliferation of endothelium and mesengial cells. The 
space in Bowman's capsule is partially obliterated. The tubules-
show albumin in the lumen. 
I 
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Fig.27. Microphotograph. Kidney from experimental rabbit immunized 
J with ROS-human DNA, H&E stain, X500. The high power view 
of g l o m e r u l u s shows focal t h i c k e n i n g s of basement 
membrane ( — • )proliferation of cells in the glomerular tuft 
showing increased number of nuclei and swelling of capillary 
tuft. 
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Fig.28. Microphotograph. Kidney from experimental rabbit immunized 
with ROS-human DNA. H&E stain, X500. The section shows 
high power view of glomerulus showing proliferation lesion 
of capillary tuft and thickened basement membrane (-—•) due 
to deposition of DNA-anti DNA antibody immune complexes. 
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Fig.29. Direct binding ELISA of SLE sera to native calf thymus 
DNA ( ^ ^ ) , native human DNA (^)andROS-humanDNA 
( H m ). Normal human sera (NHS) served as negative 
control. 
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Fig.30. Inhibition of SLE anti-DNA autoantibody to native human 
DNA, by (a) native human DNA and (b) ROS-human DNA. 
Curves (O ), ( A ), ( A )and ( • ) represent 4 different 
SLE sera nos. 1,2,3, and 4. The microtitre plates were 
coated with native human DNA (2.5 jug/ml). 
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Fig.31. Inhibition of SLE anti-DNA autoantibody binding to native 
human DNA, by (a) native human DNA and (b) ROS-human 
DNA. Curves ( O ), ( A ), ( A ) and ( # ) represent 4 
different SLE sera nos.5,6,7 and 8. The microtitre plates were 
coated with native human DNA (2.5 [xg/ml). 
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Fig.32. Inhibition of SLE anti-DNA autoantibody binding to native 
human DNA, by (a) native human DNA and (b) ROS-human 
DNA. Curves ( O ), ( A ), ( A ) and ( • ) represent 4 
different SLE sera nos. 9,10,11 and 12. The microtitre plates 
were coated with native human DNA (2.5 |ig/ml). 
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T A B L E - 10 
Inhibition of Anti-DNA Autoantibody Binding to ROS-human DNA 
S.No. Maximum percent 
inhibition at 20 |^g/ml 
Inhibitor concentration 
required for 50% 
inhibition (|ig/ml) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
60.8 
53.5 
67.0 
56.0 
55.9 
63.2 
45.4 
42.0 
38.0 
40.6 
47.0 
48.0 
12.0 
10.0 
10.0 
10.0 
15.0 
15.0 
* 50% inhibition not achieved. 
The microtitre plates were coated with native human DNA (2.5 |ig/ml) 
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TABLE-11 
Inhibition of Anti-DNA Autoantibody Binding to Native Human DNA 
S.No, 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Maximum percent 
inhibition at 20 ^g/ml 
41.3 
50.0 
50.0 
50.0 
38.8 
39.5 
33.0 
35.0 
35.0 
30.0 
36.0 
30.0 
Inhibitor concentration 
required for 50% inhibition 
(|ig/ml) 
* 
20.0 
20.0 
20.0 
* 
* 
* 
* 
* 
* 
* 
* 
* 50% inhibition not achieved 
The microtitre plates were coated with native human DNA (2.5|a,g/ml) 
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Purification of SLE IgG 
SLE IgG were purified by affinity chromatography on Protein A-
Sepharose CL-4B column. The purified IgG eluted in a single symmetrical 
peak (Fig. 33). Purity of IgG was checked by SDS-PAGE under non-reduc-
ing conditions. The purified IgG migrated as a single band (Fig. 33, inset). 
Band Shift Assay Using SLE IgG 
Band shift assay was employed to visualize the interaction of native 
and ROS-human DNA with SLE IgG. A constant amount (1 p,g) of antigen 
was incubated with varying amounts of SLE IgG (0 to 60 |ig) for 2 hrs. at 
37°C and overnight at 4"C. These immune complexes were then electro-
phoresed on 1% agarose for 2 hrs. at 30 mA. An increase in the IgG con-
centration caused an increase in the immune complex formation which re-
sulted in relative increase in the molecular weight and consequently re-
tarded mobility (Fig. 34). 
Detection of Circulating Antibodies Reactive to Native and 
ROS-human DNA in Various Cancer 
For this study, 36 serum samples were collected from patients suf-
fering from cancer of different organs/organ systems. Cancer sera were 
obtained after careful clinical examination of patients with proven 
histopathological diagnosis attending J.N.Medical College Hospital, 
A.M.U., Aligarh. Sera from normal, healthy individuals served as controls. 
The binding of circulating antibodies in cancer sera (at 1:100 dilu-
tion) with native and ROS-human DNA was assessed by direct binding 
ELISA. All the sera tested showed higher recognition to ROS-human DNA 
(Fig. 35). 
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Fig.33. Elution profile of SLE IgG on Protein A-Sepharose CL-4B 
column. Inset: SDS-PAGE of purified IgG on 7.5% 
polyacrylamide gel. 
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i Z 3 M 
Fig.34. Band shift assay of SLE IgG binding to (a) native human DNA 
I and (b) ROS-human DNA. Native and ROS-human DNA (l)ig 
i each) were incubated with 30,40,50 and 60 |ig of IgG for 2 hr. 
at 37°C and overnight at 4°C. Electrophoresis was carried out 
on 1% agarose gel for 2 hr. at 30 mA. Lane 1 contains native or 
ROS-DNA while lanes 2,3,4, and 5 contain native or ROS-
human DNA with increasing concentrations of SLE IgG. 
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Fig.35. Binding of various cancer sera to native ( ^ ^ ) and ROS-
human DNA ( ^ ^ ) . Normal human sera (NHS) serves as 
negative control. The histograms show mean absorbance values 
+/- S.D. for binding of NHS and sera from patients with cancer 
of (1, n=6) larynx, (2, n=6) breast, (3, n=6) oral cavity, (4, n=5) lung, 
(5, n=5) liver, (6, n=3) gastrointestinal tract, (7, n=l) cervix, 
(8, n=l) penis, (9, n=l) bladder and (10, n=l) bone. 
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The binding specificity of antibodies in cancer sera were analysed 
by competitive binding assay (Table. 12). Out of the 36 serum samples 
collected, six sera were from patients with cancer of larynx (five males 
aged 30 to 70 years and one female 50 years old). All these six sera were 
found to recognize ROS-human DNA to a greater extent than native hu-
man DNA (Fig. 36). The maximum percent inhibition in antibody reactiv-
ity achieved by native human DNA was lesser (23%, 16%, 59.2%, 42.5%, 
19.0%, and 62.8%) than that achieved by ROS-human DNA (30%, 42%, 
71.8%, 54.4%, 43% and 65.6%). 
Six sera were from patients suffering from breast cancer (Aged 
35 to 55 years). Five of these patients (Fig.37) had serum antibodies with 
a higher recognition to ROS-human DNA (58%, 58.7%, 54.4%, 55% and 
48.3%), whereas native human DNA inhibited to a lesser extent (49%, 
49.2%, 37.0%, 37.6% and 39.8%). One sera however, showed almost same 
amount of reactivity to native (39%) and ROS-human DNA (35%). 
Among the six serum samples from patients with cancer of oral cav-
ity (five males, 40 to 70 years old and one 30 years old female), five were 
more reactive towards ROS-human DNA ( 74.9%, 57.3%, 46.6%, 38.09% 
and 65.0%) (Fig. 38) than to its native form (52.6%, 34.9%, 32.3%, 22.4% 
and 51.0%). One sample from female patient showed higher recognition to 
native human DNA (35%) as compared to ROS-human DNA (16%). 
Five samples were collected from patients with lung cancer (four of 
these were males aged 30 to 55 years and one was a 60 years old female). 
Four patients showed higher serum antibody reactivity towards ROS-hu-
man DNA (51%, 77%, 78.4% and 45.7%) than towards native human DNA 
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TABLE -12 
Antibodies Against Native and ROS-human DNA in Cancer Sera 
Type of cancer 
Larynx 
Breast 
Oral 
Lung 
Liver 
Cervix 
Penis 
Bladder 
Rectum 
Oesophagus 
Anal 
Bone 
Non Hodgkins 
Lymphoma 
No.of sera 
tested 
6 
6 
6 
5 
5 
No.of sera 
positive* 
5 
6 
6 
5 
5 
1 
-
No.of sera 
Positive for 
ROS-human 
DNA 
2 
-
2 
2 
1 
1 
-
-
1 
1 
-
-
1 
No.of sera 
Positive for 
Native human 
DNA 
_ 
-
1 
-
-
-
-
-
-
-
-
-
-
No.of sera positive 
for both ROS and 
native human DNA 
3 
6 
3 
3 
4 
-
-
1 
-
-
1 
1 
-
* Sera were considered positive where inhibition achieved was > 35% 
The microtitre plates were coated with ROS-human DNA (2.5 jig/ml) 
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Fig.36. Detection of antibodies against (a) native human DNA, and (b) 
ROS-human DNA, in the sera of patients with cancer of larynx. 
The microtitre plates were coated with ROS-human DNA (2.5 
)ig/ml). The curves ( O ), ( • ),( A ),( A ) , (V ),and ( + ) 
represent sera from different patients with cancer of larynx. 
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Fig.37. Detection of antibodies against (a) native human DNA and (b) 
ROS-human DNA, in the sera of patients with breast cancer. 
The microtitre plates were coated with ROS-human DNA 
(2.5 ^g/ml). Curves ( V ),( O ) , ( + ) , ( ), ( A ), and 
( A ), represent sera from different patients with cancer of 
breast. 
101 
o 
55 
X 
UJ 
O 
UJ 
a 
75 
75 
(a) 
-J I • M ' ' 
(b) 
100 
0.01 0.1 10 100 
INHIBITOR CONCENTRATION ( >ig/ml) 
Fig.38. Detection of antibodies against (a) native human DNA and (b) 
ROS-human DNA in the sera of patients with cancer of oral 
cavity. The microtitre plates were coated with ROS-human DNA 
(2.5 ^ig/ml). The curves ( + ), ( O ), ( • ), ( A ), ( A ) 
a n d ( V )represent sera from different patients with cancer of 
oral cavity. 
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(33%, 43.3%, 63% and 12.6%) (Fig.39). One patient's sera showed almost 
similar amount of reactivity with native (48.4%) and ROS (47.8%) human 
DNA. 
Among the five samples of serum from patients with liver cancer, 
three were males (aged 45-50 years) and two were females (aged 38 and 50 
years). Almost all the patients had serum antibodies with higher reactivity 
towards ROS-human DNA (68.3%, 61.8%, 70% and 45.7%) than towards 
native human DNA (42%, 49.3%, 40% and 23.1%). Only the younger fe-
male patient had serum antibodies with almost similar reactivity to native 
and ROS-human DNA (40.9% and 38% respectively) (Fig. 40). 
Three samples of serum belonged to a group of patients with cancer 
of gastrointestinal tract. All these serum sample had antibodies showing 
greater reactivity towards ROS-human DNA (77.3%, 56% and 39.9%) than 
towards native human DNA (38%, 29% and 30%) (Fig. 41). 
The group of patients with miscellaneous cancers comprised of one 
patient each with cancer of cervix, penis, urinary bladder, bone and Non-
Hodgkin's lymphoma. Maximum percent inhibition, of serum from these 
patients, achieved by ROS-human DNA was 46%, 25%, 46.1% 60.7% and 
56% respectively (Fig. 42b). Native human DNA was inhibitory to a lesser 
extent, showing maximum inhibition of 33%, 17.4%, 34.7%, 53% and 18% 
respectively. (Fig. 42a). These results have been summarized in Table. 13. 
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Fig.39. Detection of antibodies against (a) native human DNA and (b) 
ROS-human DNA, in the sera of patients with cancer of lung. 
The microtitre plates were coated with ROS-human DNA (2.5 
^g/ml). The curves ( V ), ( A ), ( A ), ( O ) and ( • ) 
represent sera from different patients with lung cancer. 
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Fig.40. Detection of antibodies against (a) native human DNA and (b) 
ROS-human DNA in the sera of patients with liver cancer. The 
microtitre plates coated with ROS-human DNA (2.5 )ig/ml). 
The curves ( A ), ( A ), ( v ) , ( O ) a n d ( # )represent sera 
from different patients with cancer of liver. 
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Fig.41. Detection of antibodies against (a) native human DNA and (b) 
ROS-human DNA, in the sera of patients with cancer of 
gastrointestinal tract. The microtitre plates were coated with 
ROS-human DNA (2.5 ^g/ml). The curves ( O ) , ( A ) a n d 
( A ) represent sera from different patients with cancer of 
gastrointestinal tract. 
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Fig.42. Detection of antibodies against (a) native human DNA, and (b) 
ROS-human DNA in the sera of patients with cancer of 
cervix ( O ), penis (A ), urinary bladder ( • ), bone ( v ) and 
Non-Hodgkin's lymphoma ( • ). The microtitre plates were 
coated with ROS-human DNA (2.5 ng/ml). 
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TABLE - 13 
Inhibition of the Binding of Antibodies in Cancer Sera to ROS-human DNA 
by Native and ROS-human DNA 
Type of cancer No. of sera Maximum percent inhibition at 20 ug/ml by; 
tested Native-human DNA ROS-human DNA 
Larynx 
Breast 
Oral 
Lung 
Liver 
Gastrointestinal tract 
Cervix 
Penis 
Bladder 
Bone 
Non-Hodgkin's-
Lymphoma 
6 
6 
6 
5 
5 
3 
23.0 
16.0 
62.8 
59.2 
42.5 
19.0 
49.0 
39.0 
42.2 
37.0 
37.6 
39.8 
52.6 
34.9 
32.3 
22.4 
51.0 
35.0 
33.0 
43.3 
63.0 
48.4 
12.0 
42.0 
40.9 
49.3 
40.0 
23,1 
28.5 
29.9 
38.4 
33.0 
17.4 
34.7 
53.0 
18.0 
30.0 
42.0 
65.6 
71.8 
54.4 
43.0 
58.0 
35.0 
58.7 
54.4 
55.0 
48.3 
74.9 
57.3 
46.6 
38.0 
65.0 
16.0 
51.0 
77.0 
78.4 
47.8 
45.7 
68.3 
38.0 
61.8 
70.0 
45.7 
39.9 
56.0 
77.3 
46.0 
25.0 
46.1 
60.7 
56.0 
The microtitre plates were coated with ROS-human DNA (2.5 ^g/ml) 
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Detection of Antibodies in Sera of Various Cancer Patients 
Before and After Radiotherapy 
Radiotherapy was performed on a different patients suffering from 
various cancers such as larynx, oral, breast, gall bladder and lung. The 
circulating autoantibodies in serum samples collected from these patients 
before and after therapy were assessed for their binding specificity to na-
tive and ROS-human DNA. Results of direct binding assay of cancer sera 
(at 1:100 dilution) showed that the binding of circulating antibodies to 
both native (Fig. 43a) and ROS-(Fig. 43b) human DNA was decreased fol-
lowing radiotherapy of the patients. 
The binding specificity of these cancer autoantibodies to native and 
ROS-human DNA was analysed by competitive ELISA. The circulating 
antibodies in sera collected after therapy were found to recognize both 
native and ROS-human DNA to a lesser extent, as is evident from de-
creased value of maximum percent inhibition achieved by either native or 
ROS-human DNA (Table. 14). 
Purification of Cancer IgG 
Cancer IgG was isolated and purif ied from cancer sera by affinity 
chromatography on Protein A-Sepharose CL-4B column. The IgG eluted 
in a single symmetrical peak (Fig. 44). Its purity was checked by SDS-
PAGE under non-reducing conditions, which resulted in a single band (Fig. 
44 of inset). 
Band Shift Assay with Cancer IgG 
Band shift assay was performed for the visual detection of interac-
tion of native and ROS-human DNA with purified cancer IgG. A constant 
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Fig.43. Binding of various cancer sera collected before ( ^ ^ ) and 
after ( ^ ^ ) radiotherapy to (a) native human DNA and (b) 
ROS-human DNA. The histograms show mean absorbance +/-
S.D. for binding of NHS and sera from patients with (1, n=6) 
oral, (2, n=4) larynx, (3, n=2) breast, (4, n=l) gall bladder and 
(5, n=l) lung cancer. 
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TABLE- !4 
Inhibition of Various Cancer Autoantibodies by Native and ROS-
human DNA as Monitored Before and After Radiotherapy. 
Type of cancer Maximum percent inhibition at 20 |xg/ml 
Native human DNA RQS-human DNA 
Before therapy After therapy Before therapy After therapy 
Oral 
Larynx 
Breast 
Gall bladder 
Lung 
38.1 
31.0 
36.2 
32.3 
53.3 
46.4 
34.0 
2L2 
61.0 
42.0 
38.0 
44.9 
45.3 
36.5 
17.6 
17.2 
22.0 
50.0 
40.7 
16.5 
39.0 
29.6 
53.0 
30.6 
19.5 
32.0 
51.6 
40.0 
54.1 
63.0 
66.7 
61.2 
40.0 
53.7 
66.5 
64.0 
41.0 
60.4 
61.2 
37.6 
28.9 
44.7 
58.0 
63.0 
26.4 
34.0 
28.0 
35.5 
17.1 
26.5 
36.2 
40.0 
The microtitre plates were coated with ROS-human DNA (2.5 |j,g/ml) 
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Fig.44. Elution profile of cancer IgG on Protein A-Sepharose CL-4B 
column. Inset: SDS-PAGE of purified IgG on 7.5% 
polyacrylamide gel. 
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amount (1 |j,g) of antigen was incubated with increasing concentration (0 
to 100 jig) of cancer IgG for 2 hrs. at 37"C and overnight at 4"C. Immune 
complexes hence formed were electrophorsed on 1% agarose for 2 hrs. at 
30 mA (Fig. 45). The gel visualized under UV light revealed formation of 
high molecular weight immune complexes which resulted in retarded mo-
bility of the nucleic acid on agarose gel. 
Detection of Oxidative Lesions in DNA 
DNA was isolated from lymphocytes of various cancer patients. The 
purity and concentration of the DNA preparations were ascertained by A^^^ 
and A^ gp measurements. DNA isolated from lymphocytes of normal healthy 
individuals were used as controls for this study. 
Anti-ROS-human DNA-IgG was used as probe to detect oxidative 
lesions in the DNA from cancer patients. Immune complexes, formed by 
incubating a fixed amount (60 i^g) of anti-ROS-human DNA-IgG with in-
creasing concentrations (0 to 20 |ig/ml) of DNA were coated on microtitre 
plates already coated with ROS-human DNA (2.5 ng/ml) 
Out of the three DNA samples isolated from different patients with 
breast cancer (Fig. 46) two showed a high inhibition (56.3% and 60%) of 
immune IgG binding to immunogen, and one showed moderate amount of 
inhibition (42%). 
Another three samples of DNA were from cancer of head and 
neck (Fig. 46). Again two of these DNA samples showed a high inhi-
bition (53% and 57%) of antibody binding and one sample showed 
moderate amount of inhibition (46%).One sample of lung cancer 
1 1 3 
Cb3 
1 2 3 Lf 5-
Fig.45. Band shift assay of cancer IgG binding to (a) native human 
DNA and (b) ROS-human DNA. Native and ROS-human DNA 
( 1 |xg each) were incubated with 25, 50, 75 and 100 jig of IgG 
for 2 hrs. at 37°C and overnight at 4°C. Electrophoresis was 
performed on 1% agarose gel for 2 hrs. at 30 mA. Lane 1 
contains native or ROS-human DNA while lanes 2, 3, 4 and 5 
contain native or ROS- human DNA with increasing 
concentrations of cancer IgG. 
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Fig.46. Inhibition of binding of anti-ROS-human DNA-IgG by genomic 
DNA isolated from lymphocytes of patients with breast cancer. 
The microtitre plates were coated with ROS-human DNA (2.5 
[ig/ml). The curves ( O ), ( A ) and ( A ) represent DNA 
isolated from different individuals with breast cancer. 
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showed a moderate inhibition (32.5%) (Fig. 47). 
Two DNA samples isolated from cancer of gall bladder showed high 
inhibition (58% and 54%) of antibody activity ( Fig.48),all the three DNA 
samples from patients with cancer of cervix showed high inhibition (62.7%, 
69% and 76%) of antibody binding (Fig. 49). 
On the contrary, DNA isolated from normal healthy individuals 
showed negligible inhibition (19% and 25%) of anti-ROS-human DNA-
IgG binding to the immunogen (Fig. 50). These results have been summa-
rized in Table. 15. 
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Fig.47. Inhibition of binding of anti-ROS-human DNA IgG by genomic 
DNA isolated from lymphocytes of patients with head, neck 
and lung cancer. The microtitre plates were coated with ROS-
human DNA (2.5 /ig/ml). The curves ( O ), ( • ) and 
( A ) represent DNA isolated from different individuals with 
cancer of head and neck. Thecurve( • )represents DNA isolated 
from a patient with lung cancer. 
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Fig.48. Inhibition of binding of anti-ROS-human DNA-IgG by genomic 
DNA isolated from lymphocytes of patients with cancer of gall 
bladder. The microtitre plates were coated with ROS-human 
DNA (2.5 jig/ml). The curves ( A )and ( O )represent DNA 
isolated from two different individuals with cancer of gall 
bladder. 
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Fig.49. Inhibition of binding of anti-ROS-human DNA-IgG by genomic 
DNA isolated from lymphocytes of patients with cancer of 
cervix. The microtitre plates were coated with ROS-human 
DNA (2.5 ^g/ml). The curves ( O X ( A ) and ( A ) repre-
sent DNA isolated from different individuals with cancer of 
cervix. 
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Fig.50. Inhibition of binding of anti-ROS-human DNA-IgG by genomic 
DNA isolated from lymphocytes of normal individuals. The 
microtitre plates were coated with ROS-human DNA (2.5 ^ig/ 
ml). The curves ( O ) and ( A ) represent DNA isolated from 
two different normal individuals. 
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TABLE-15 
Binding of Anti-ROS-human DNA-IgG to DNA Isolated from 
Lymphocytes of Cancer Patients 
Type of cancer 
Breast 
Head and Neck 
Lung 
Gall Bladder 
Cervix 
No.of J 
tested 
3 
3 
1 
2 
3 
samples Maximum percent inhibition 
at 20 (xg/ml 
56.3,60.0,42.0 
53.0,57.0,46.0 
32.5 
58.0, 54.0 
62.7,69.0,76.0 
The microtitre plates were coated with ROS-human DNA (2.5 |ig/ml) 
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Reactive Oxygen Species (ROS), formed continuously as a 
consequence of both biochemical reactions and external factors are involved 
in a diversity of important phenomenon in medicine, such as mutagenesis, 
carcinogenesis, aging and various diseases involving inflammatory process 
(Halliwell and Aruoma, 1991; Ames et al., 1995; Pryor, 1997). Although, 
aerobes have developed antioxidant defence to control harmful effects of 
activated oxygen species (Lunec and Blake, 1990; Sandstrom et al., 1993; 
Singh et al., 1994) a certain fraction escapes the cellular defences. This 
can happen if antioxidants are depleted and/or if the formation of reactive 
oxygen species is increased beyond the ability of the defence to cope with 
them (Sies, 1991). 
The ROS which escapes cellular defence causes permanent or 
transient damage to important biomolecules such as proteins, lipids and 
nucleic acids (Breen and Murphy, 1995; Wiseman and Halliwell, 1996). 
The chronic production of DNA damage by ROS is consistent with the 
current concept of carcinogenesis in which multiple genetic changes, such 
as activation of oncogenes or inactivation of tumor suppressor genes 
appears to be critical (Harris and HoUstein, 1993; Du et al., 1994; Loft 
and Poulsan, 1996). Induction of mutation following DNA damage 
represents a failure of the repair system to remove DNA damage and is 
one of the critical events in carcinogenic transformation and other human 
pathologies (Henley and Linn, 1997; Moller and Wallin, 1998). 
In vivo much of the oxidative damage to DNA results from the 
deleterious reactions with hydroxyl radicals (*0H), which are generated 
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by the metal ion-dependent conversion of superoxide radicals (O^' ) and 
hydrogen peroxide or by the interaction of ionizing radiations with cellular 
water (Haber and Weiss, 1934; Halliwell, 1992; Luft, 1994). 
Hydroxyl radicals can cause many different types of DNA damage, 
including strand breaks, formation of apurinic/apyrimidinic sites and base 
modification such as formation of 8-hydroxydeoxyguanosine (8-OHdG) 
thymine glycol and ring opened base products (Breimer, 1990). Elevated 
levels of 8-OHdG, a promutagenic hydroxyl radical induced lesions, in 
DNA of cancerous tissues further supports the role of ROS in cancer 
development (Olinski et al., 1992; Malins et al., 1993). 
An important role of oxidative DNA damage has also been suggested 
in autoimmune diseases such as systemic lupus erythematosus (SLE) 
(Halliwell and Gutteridge, 1989; Bashir et al., 1993). SLE is a prototype 
immune complex disease in which anti-DNA autoantibody-DNA complexes 
deposit in the tissue and induce inflammation (Naparstek and Madaio, 
1997). Both genetic and environmental factors are believed to contribute 
to this disease (Steinberg et al., 1991). The presence of anti-DNA 
autoantibodies in the sera of SLE patients has long been considered as a 
marker of SLE as well as the pathogenic factor for its renal disease 
manifestations (Koffler, 1974). 
Lymphocytes isolated from SLE patients have been found to contain 
elevated levels of 8-OHdG (Bashir et al., 1993). This DNA with oxidative 
lesions may be a source of the DNA autoantibodies that are characteristic 
of SLE (Blount et al., 1992). Accordingly, since SLE patients may suffer 
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from an increased rate of oxidative DNA damage and also a deficient repair 
mechanism, they are at an increased risk of malignant diseases (Bashir et 
al., 1993, Lunec et al., 1994). 
In the present study, hydroxyl radical generated by ultraviolet light 
irradiation of hydrogen peroxide caused extensive damage to DNA bases 
and sugar residues, leading to single strand breaks. The damage to 
nitrogenous bases, resulted in destruction of chromophoric groups as 
revealed by the ultraviolet light absorption spectra of ROS-human DNA 
which exhibited hypochromicity at 260 nm. 
Circular dichroism (CD) is extremely sensitive even to small changes 
in mutual orientation of the neighbouring bases in polynucleotides (Ivanov 
et al., 1973). Thus, the decreased ellipticity in CD spectra of ROS-human 
DNA as compared to its native form indicates reduced base stacking due 
to single strand breaks in the modified DNA. Base stacking and hydrogen 
bonding interaction are known to stabilize the native structure of DNA, 
thus high temperature which disrupts these interact ions favours 
denaturation of DNA (Casperson and Voss, 1983; Thomas, 1993). The 
lowered melting temperature of ROS-human DNA suggests reduced base 
stacking, single strand breaks, disruption of hydrogen bond and a 
consequent helix disruption in DNA following attack by ROS. 
Comparison of sedimentation rates for alkali digested native and 
ROS-human DNA revealed, diffused sedimentation profile of ROS-human 
DNA due to decrease in molecular weight as a result of single strand breaks. 
On the other hand sedimentation profile of native human DNA showed a 
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sharp symmetrical peak. Generation of single strand breaks in ROS modified 
human DNA was further confirmed by hydroxyapat i te column 
chromatography. Hydroxyapatite has a greater affinity towards rigid ordered 
structures than flexible, disordered ones (Bernardi, 1965 & 1969). The 
elution of a fraction of ROS-human DNA from hydroxyapatite column by 
the lower strength buffer (125 mM Na-K-phosphate buffer) indicates 
presence of single strand breaks and a resultant local perturbation in the 
secondary structure of ROS-human DNA. Native human DNA was eluted 
only by the higher strength buffer (250 mM Na-K-phosphate buffer) 
indicating its greater affinity for hydroxyapatite matrix and hence presence 
of a regular and intact secondary structure. 
The structural alterations in DNA following damage by various agents 
may at times by large enough to act as substrate for single strand specific 
nuclease (Kato and Fraser, 1973; Slor and Lev, 1973; Shishido and Ando, 
1974; Yamasaki et al., 1977). In view of this, native and ROS-human DNA 
were subjected to nuclease SI digestion. The results, showed partial 
digestion of ROS-human DNA on treatment with nuclease SI, while native 
human DNA remained undigested. This observation clearly demonstrates 
that sufficient single strand breaks are generated in DNA by hydroxyl 
radical rendering it susceptible to digestion by single strand specific 
nuclease SI. 
The extent of modification in individual bases of human DNA 
following attack by hydroxyl radicals was assessed by fractionation of 
ROS-human DNA on DEAE Sephadex A-25 column chromatography. The 
data indicates that hydroxyl radical was able to modify all the four bases. 
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However, in consistence with earlier findings, thymine and guanine showed 
greater susceptibility to modification by hydroxyl radicals (Demple and 
Linn, 1982; Hutchinson, 1985; Yamamoto and Kawanishi, 1989; Rosen et 
al., 1996). 
Immunogenicity of human DNA was analyzed by immunizing its 
native and ROS modified forms into rabbits. The immunological data 
suggests ROS-human DNA to be a potent immunizing stimulus inducing 
high titre antibodies whereas native human DNA and human DNA treated 
with UV or H2O2 alone were found to be weak immunogens. The results 
reiterate earlier studies which show that although native DNA per se is a 
poor immunogen however, its oxidatively damaged/analog with altered bases 
and conformational variance from B-form, can trigger immune response 
(Lafer etal., 19S1; Lee et al., 1984; Santella ^/^/., 1985; Sundquist ^r a/., 
1987). Double stranded RNA, RNA-DNA hybrids, double helical 
polydeoxyribonucleotides, DNA modified with drugs and hormones too 
have been found to induce antibodies (Anderson et al., 1988; Burlingame 
et al., 1993; Desai et al., 1993; Mohan et al., 1993; Moinuddin and Ali, 
1994; Arjumand et al., 1995; Theofilopoulous, 1995). 
The antigenic specificity of anti-ROS-human DNA-IgG was 
ascertained by competition binding assay. Anti-ROS-human DNA-IgG was 
found to have high affinity for its immunogen as only 0.1 [ig/ml of 
immunogen was required to inhibit 50% antibody activity. Besides, this, 
the immune IgG also showed some amount of cross-reactivity towards 
native human DNA. This may be possible because of similarity in the sugar-
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phosphate backbone or common antigenic determinants of native and 
modified DNA (Lafer et al., 1981; Ranch et al., 1985). 
In order to facilitate the detection of interaction between immune 
IgG and immunogen, gel retardation assay was carried out. The results 
revealed a high affinity of anti-ROS-human DNA-IgG for its immunogen. 
Besides, the specific binding of anti-ROS-human DNA-IgG was also 
observed with native human DNA. These results further reiterated that 
induced antibodies react with antigenic determinants common to both native 
and ROS-human DNA. 
Native calf thymus and mitochondrial DNA also showed moderate 
amount of reactivity with the immune IgG because of their common 
mammalian origin. Higher binding to ROS-calf thymus DNA, ROS-RNA 
and ROS-poly (G) than to their unmodified analogs, demonstrates with 
preferential recognition of ROS-modified epitopes by immune IgG. DNA 
modified by superoxide radical (02'") however, inhibited antibody activity 
to a lesser extent possibly because damage inflicted on DNA by Oj^'is less 
severe than that by hydroxyl radical (Fischer-Nielsen etal., 1994). 
Brominated DNA exhibiting Z-conformation and poly (rG) poly (dC), 
a polymer known to attain A-/ analogus conformation, inhibited IgG activity 
poorly, indicating absence of any major conformational alteration in ROS-
human DNA. Besides binding to various nucleic acids and synthetic 
polynucleotides, the anti-ROS-human DNA-IgG also showed cross-
reactivity to some nuclear proteins (histones, ribonucleoproteins) and also 
towards chondriatin sulphate and cardiolipin. It has been suggested that 
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phosphate-sugar-phosphate moiety of cardiolopin mimics the backbone 
of DNA, thus explaining the cross-reactivity of immune IgG (Ranch et al., 
1984). Analysis of the data indicates that anti-ROS-human DNA-IgG is 
polyspecific and the various cross-reacting antigens with which it reacts 
shares a common antigenic determinant or epitope. 
Anti-DNA-autoantibodies, the hallmark of SLE are also known to be 
polyspecific and many studies suggest that their pathogenic mechanism in 
vivo is probably through reactivity with molecules other than DNA. These 
cross-reactive molecules include heparan sulphate, chondriatin sulphate, 
hyaluronic acid, vimentin and phospholipids which are present in 
glomerular basement membrane (Andre-Schwartz et al., 1984; Faaber et 
al., 1984; Jacob et al., 1984; Faaber et al., 1986; Chen et al, 1989; 
Kashihara et al., 1993). Accordingly it is speculated that in vivo antibodies 
to ds DNA may directly bind to the glomerular antigens and adversely affect 
the function of kidney by causing glomerular immune deposition (Madaio 
et at., 1987; Raz et al, 1989). 
The polyspecific behaviour exhibited by SLE anti-DNA 
autoantibodies suggests that native DNA itself may not be the immunogen 
responsible for their production and the binding of these autoantibodies to 
dsDNA may be a non specific cross-reactive event (Zack et al, 1995). 
Thus, the exact antigen responsible for anti-DNA autoantibody production 
in SLE patients remains an engima. Efforts are underway to generate 
antibodies against antigens, which cross-react with native DNA theteby 
mimicking the SLE autoantibodies (Halliwell and Gutteridge, 1985; 
128 
Sundquist et al., 1987; Ames, 1989; Desai et al., 1993; Blount et al., 1994; 
Ara and Ali., 1995; Arif and Ali., 1995). 
In the present study, polyspecific behaviour of anti-ROS-human DNA-
IgG in a way resembles the binding characteristics of SLE anti-DNA 
autoantibodies thus suggesting a some what common origin i.e. ROS-human 
DNA. The rabbit immunized with ROS-human DNA exhibited SLE like 
disease conditions. Light microscopic studies of renal biopsy reveals 
glomerular nephritis while immunofluorescence studies show typical 
deposit of immune complexes in the glomeruli. 
The antigenicity of ROS-human DNA was further investigated by 
characterizing SLE autoantibodies for their binding towards native and 
modified DNA. The SLE autoantibodies react with dsDNA from a wide 
range of species (Pisetsky, 1996). In this study, comparative binding of 
SLE autoantibodies to DNA from calf thymus and human placenta was 
analysed. As reported earlier the SLE autoantibodies seemed to be more 
specific for human DNA (Yui et al., 1996). Thus, in order to optimize 
binding conditions, further characterization of SLE autoantibodies was 
performed using human placental DNA as coating antigen rather than the 
more conventional calf thymus DNA. 
The binding specificities of SLE anti-DNA autoantibodies were 
investigated by competition ELISA. ROS-human DNA could inhibit SLE 
antibody activity to a maximum of 67% whereas native human DNA could 
achieve a maximum inhibition of 50%. These results suggest stronger 
reactivity of ROS-human DNA towards SLE autoantibodies. The binding 
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of SLE IgG to native and ROS-huinan DNA was visually detected in band 
shift assay. These findings are consistent with earlier work of Blount et 
al. (1989), which suggested that ROS modification of DNA results in 
increased binding of SLE autoantibodies. Thus ROS modified human DNA 
could be a plausible candidate for the origin of anti-DNA autoantibodies 
in SLE (Stollar, 1986; Zouali et al., 1988; Hasan et al, 1991). 
It has been proposed that in chronic inflammatory diseases such as 
SLE, the phagocytic cells release reactive oxygen species (Allan et al., 
1988) which penetrate cellular membranes and react with nuclear DNA 
(Bashir, et al., 1993). Subsequent release of this altered DNA during 
apoptosis, may enable it to act as an antigen inducing antibodies cross-
reacting with native DNA (Herrmann et al., 1996; Casciola-Rosen and 
Rosen, 1997). 
Epidemiologic studies confirmed an increased cancer incidence for 
most of the chronic inflammatory diseases such as chronic hepatitis, 
systemic sclerosis and SLE (Boumpas et al., 1986; Petterson et al., 1992; 
Lunec et al., 1994). A high frequency of lymphoreticular neoplasia was 
observed in New Zealand Black Mice the classical animal model for lupus 
erythematosus. These mice exhibited an increased in chromosomal breaks, 
associated with increased anti-DNA antibody formation (Emerit et al., 
1981). Furthermore, many studies have reported elevated levels of 
antinuclear antibodies in sera of patients with malignancies. (Zeronski et 
al., 1972; Bunham, 1972; Tannenberg et al., 1973; Wasserman et al., 1975; Swissa 
et al., 1990; Chagnaud et al., 1992; Faiderbe et al, 1992; Becker et al, 1994). 
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Based on the premise that inflammatory conditions, in cancer induce 
the production of ROS which causes DNA damage and on the fact many of 
these patients develop anti-DNA autoantibodies (Niwa et al., 1985; Cross 
et al., 1987; Blount et al., 1992; Frenkel, 1992). In the present study, serum 
of cancer patients were tested for the presence of autoantibodies reactive 
towards native and ROS-human DNA. In direct binding ELISA, all the 
cancer sera tested showed higher recognition of ROS-human DNA by the 
circulating autoantibodies. The antigenic specificity of circulating 
antibodies was analyzed by competition binding assay. 
Out of the various cancer sera tested, a large group belonged to 
patients suffering from malignancies of respiratory system, such as cancer 
of larynx, lung and oral cavity. The primary cause of these malignancies 
involves addiction to tobacco (chewing and smoking) which is quite 
prevalent in India and is known to enhance production of ROS in vivo 
(Nair et al., 1992; Leanderson, 1993). Hence, ROS is implicated in etiology 
of malignances of respiratory system (Wyder and Hoffman, 1994). Higher 
binding to ROS-human DNA exhibited by more than 80% of serum samples 
collected from patients with malignancies of respiratory system suggests 
the involvement of ROS modified DNA in development of cancer of 
respiratory system. 
Patients suffering from breast cancer ( 5 out of 6) showed a higher 
reactivity towards ROS-human DNA than to its native analog. These results 
reiterate previous findings which suggest involvement of ROS damaged 
DNA in induction and progression of breast cancer (Jaiyesimi, et al., 1992; 
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Malins et al., 1993 & 1996). Clinical significance of autoantibodies in 
cancer is unclear, however, the presence of anti-nuclear antibodies do 
indicate a worse prognosis or a more frequent recurrence of breast cancer 
(Wasserman et al, 1975; Turnbull et al., 1978). 
Hepatocellular carcinoma also strongly correlates with oxidative 
DNA damage (Olinski et al., 1992; Okamoto et al., 1994), since it is actively 
associated with chronic hepatitis virus B and C which results in enhanced 
generation of ROS as a result of inflammation (Blumberg et al., 1975; 
Shimoda et al., 1994). In the present investigation serum samples from 
hepatocellular carcinoma ( 4 out of 5) showed, greater recognition of ROS-
human DNA, thus suggesting role of ROS damage to DNA in the 
development of this disease. 
Oxygen derived free radicals have also been implicated in mechanism 
of gastric (Salim, 1992a) and colonic cancer (Salim, 1992b). Results 
obtained from serum of patient with gastrointestinal tract cancer support 
this view since all the three serum samples showed higher recognition of 
ROS-human DNA than the native DNA. Similar results were obtained with 
serum from cancer of prostate, cervix, urinary bladder, bone and Non-
Hodgkin's lymphoma. All these sera showed preferential reactivity with 
ROS-human DNA as compared to its native analog. 
The data presented suggests that naturally occurring circulating 
autoantibodies in cancer patient have higher reactivity towards ROS 
modified DNA than towards native DNA. ROS appears to enhance 
antigenicity of native DNA, thus suggesting role of ROS damaged DNA in 
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production of autoantibodies in cancer patients. 
A preliminary study, was also performed in a group of cancer patients 
undergoing radiotherapy. Radiation induced alterations in the number and 
function of peripheral blood lymphocytes have previously been described 
in patients treated with radiotherapy for carcinoma of breast (Stratton et 
al., 1975), lung (Braeman et al., 1974), bladder (OTool et al., 1972), 
uterine cervix (Stralton, et al., 1975) testicular seminoma and carcinoma 
(Millard, 1965) and Hodgkin's disease (Anderson, 1974). Most studies 
demonstrate an acute lymphocytopenia and suppression of immune function 
shortly after the initation of treatment (Stratton et al., 1975; Millard, 1965). 
Long term effects of radiotherapy on the number and immune function of 
peripheral blood lymphocytes have also been described (Fuks et al., 1976). 
In the present investigations done on patients with cancer of oral cavity, 
larynx, breast, gall bladder and lung exhibited decrease in level of serum 
antibodies against native and ROS-human DNA, following radiotherapy. 
The recognition of native and ROS-human DNA by cancer antibodies 
was visually detected in gel retardation assay. The role of ROS modified 
DNA in development of cancer is supported by the abundant presence of 
oxidative lesions in DNA from cancerous tissues (Olinski et al., 1992). 
Presence of oxidative damage in genomic and mitochondrial DNA from 
tissue and isolated cells may be studied by a variety of methods such as 
Gas chromatography/mass spectroscopy (Dizdaroglu, 1991) and HPLC-EC 
assay (Floyd et al., 1986; Cadet et al., 1997). Immunological detection of 
DNA lesions have recently been introduced with slot blot based estimation 
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of 8-oxo-dG in intact isolated DNA by means of polyclonal antibodies 
(Musarrat and Wani, 1994) or ELISA base estimation of 8-oxo-dG in DNA 
digested to nucleosides and purified by an immunoaffinity column (Yin et 
al., 1995). 
In the present study, attempts have been made to detect the oxidative 
lesions in DNA isolated from lymphocytes of various cancer patients by 
using anti-ROS-human DNA IgG as an immunochemical probe. 
DNA was isolated from lymphocytes of a group of twelve patients 
suffering from cancer of either breast, head and neck, lung, gall bladder or 
cervix. DNA from patients with breast cancer recognized anti-ROS-human 
DNA-IgG appreciably and inhibited its activity in the range of 42% to 60%. 
The results indicate presence of ROS induced lesions in DNA from patients 
with breast cancer. Previously, elevated levels of 8-hydroxyadenine and 
8-hydroxyguanine which are markers of oxidative DNA damage, have been 
detected in DNA of breast cancer patients (Malins et al., 1996; Musarrat 
et al., 1996). DNA from patient with head and neck cancer too inhibited 
antibody activity appreciably, ranging from 46% to 57%. Lung cancer DNA 
exhibited 32.5% inhibition and DNA from patients with gall bladder 
cancer showed 54% and 58% inhibition. Inhibition of antibody activity 
achieved by DNA from patients with cancer of cervix was highest ranging 
from 62.7% to 76%. All these results indicate effective binding of anti-
ROS-human DNA-IgG to DNA isolated from various cancer patients and 
confirms presence of ROS induced oxidative DNA lesions in cancer patients. 
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Based on this study, the following conclusions can be drawn: 
1. The exposure of human DNA to reactive oxygen species resulted in 
certain structural alterations such as single strand breaks, disruption 
of hydrogen bonds and a consequent helix destabilization. 
2. ROS, modified all the four bases in human DNA. However, thymine 
and guanine showed greater susceptibility to modification by ROS. 
3. ROS-human DNA was found to be thermally less stable than its native 
analog. 
4. ROS induced modification in DNA rendered it immunogenic inducing 
high titre antibodies. 
5. The anti-ROS human DNA antibodies though, highly specific for the 
immunogen exhibited some cross-reactivity with various nucleic 
acids, synthetic polynucleotides and nuclear proteins thus resembling 
binding characteristics of SLE anti-DNA antibodies. 
6. Deposition of immune complexes and development of glomerular 
nephritis observed in kidneys of rabbits immunized with ROS-human 
DNA, suggests development of SLE like features in these 
experimental animals. 
7. Circulating SLE anti-DNA antibodies were found to be more reactive 
towards ROS-human DNA than native human or calf thymus DNA. 
8. Antibodies in sera of various cancer patients were found to be more 
specific for ROS-human DNA than for its native analog. 
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9. The antibody level and its reactivity was decreased in cancer patients 
after radiotherapy. 
10. Oxidative lesions were detected in DNA isolated from lymphocytes 
of cancer patients using anti-ROS-human DNA-IgG as probe. 
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